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Abstract
Recent data has suggested that disruption of the dystrophin-glycoprotein complex
(DGC) may be involved in mediating the progression of cardiac hypertrophy and failure.
Here we examined the regulation of DGC proteins in the hearts of adult (6 months), aged
(30 months), and very aged (36 months) F344/N X BN rats . Compared to adult animals,
the content of α- and β-dystroglycan were 6.93 ± 5.16% and 58.36 ± 3.64% higher,
respectively (P < 0.05) in very aged animals. Immunoblotting and immunhistochemical
analysis suggested that aging appeared to diminish alpha-sarcoglycan, beta-sarcoglycan
and delta-sarcoglycan content by 13.89 ± 3.1%,15.8 ± 2.8% and 18.63 ± 3.04%,
respectively (P < 0.05). These alterations in the DGC occurred coincident with ageassociated alterations in cytoplasmic anti-rat IgG immunoreactivity, TUNEL positive
nuclei, alpha-fodrin cleavage, indices of caspase-3 activation and diminished AKT
phosphoryation (Ser 308). Taken together, these data suggest that aging alters cardiac
DGC structure and function.
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Chapter 1
INTRODUCTION
It is estimated that by the year 2035, nearly one in four individuals will be 65
years of age or older [1]. In the United States, cardiovascular disease e.g., atherosclerosis
and hypertension, is the leading cause of mortality, accounting for over 40 percent of
deaths in those aged 65 years and above [1]. The aged heart has a diminished functional
and adaptive reserve capacity, an increased susceptibility to incur damage (e.g., as a
result of ischemia), and a limited practical ability for repair/regeneration [2]. The
mechanism(s) responsible for these phenotypic changes are not well understood.
Cardiac structure and function are remarkably similar among mammalian species,
and the use of animal models has been extremely helpful in developing treatment
strategies for alleviating heart disease in humans. The Fischer 344/Brown Norway F1
hybrid rat (F344/N X BN ) is recommended for age-related studies by the National
Institutes on Aging (NIA) as this hybrid rat lives longer and has a lower rate of
pathological conditions than inbred rats.

Previous studies using the F344/N X BN rat

strain have demonstrated that aged F344/N X BN rat

hybrid animals exhibit left

ventricular hypertrophy, dilatation, persistent arrhythmias and fibrosis of the heart [3].
These findings suggest that similar to most human studies, cardiac muscle in these
animals undergo structural and functional changes with age. Similar to humans, the
precise cellular and molecular mechanism(s) underlying these changes remain elusive.
The dystrophin glycoprotein complex (DGC) is a group of tightly associated
transmembrane and cytoskeletal proteins that forms a molecular bridge between
dystrophin and the extracellular matrix [4]. DGC is formed by dystrophin, dystroglycan
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complex (α- and β-DG ), sarcoglycans ( α, β, γ and δ ), sarcospan, syntrophins (α-1, β-1
and β-2 ) and dystrobrevins. Dystrophin is absent from the muscles of patients affected
by Duchenne muscular dystrophy (DMD) whereas the milder Becker muscular dystrophy
(BMD) is characterized by several mutations that reduce dystrophin levels or result in the
formation of a partially functional isoform [5]. Similar to dystrophin, the sarcoglycans
may also be involved as mutations to the sarcoglycan genes have been shown to cause the
limb-girdle muscular dystrophies (LGMD) [6, 7]. Recent data suggests that the disruption
of dystrophin or dystrophin associated proteins (DAP) may also play a role in cardiac
failure [8]. For example, cardiomyocytes lacking dystrophin are abnormally vulnerable to
mechanical stress-induced injury, and are characterized by inappropriate calcium influx,
aberrant cell signaling, increased oxidative stress, and alterations in contractile function
[9].
Interestingly, the aging mammalian heart exhibits many of these same
characteristics [10-15]. Although not investigated, given the similarity between the aging
and dystrophic heart it is possible that alterations in the DGC may be involved. Similarly,
while the proteins of specific compartments of the DGC and their role in muscular
dystrophies are well described, to our knowledge little is known about their regulation in
cardiac muscle with aging.
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PURPOSE
Our long term goal is to identify the cellular and molecular mechanisms
underlying the age associated changes in cardiac muscle causing progressive impairment
of cardiac function. The purpose of this study is to investigate how aging affects the DGC
structure and function in the F344/N X BN rat heart.

SPECIFIC AIMS
It is estimated that by 2053, nearly one in four individuals in the United States
will be sixty-five years of age or older. Advancing age is associated with left ventricular
hypertrophy, dilatation, and fibrosis of the heart with alteration in cardiac morphology
and increased incidence of cardiac arrhythmias. Recent data has suggested that disruption
of the dystrophin-glycoprotein complex (DGC) may be involved in mediating the
progression of cardiac hypertrophy and failure [59]. We hypothesize that age-related
alterations in the DGC may mediate age-associated cardiac dysfunction. To test this
hypothesis, two specific aims will be pursued.

Specific Aim #1
To investigate how aging in the F344/N X BN rat affects cardiac DGC structure.
Hypothesis: Aging in the F344/N X BN RAT rat heart will be associated with
alterations in DGC protein levels and localization.

Specific Aim #2
To investigate how aging in the F344/N X BN rat affects cardiac DGC function.
Hypothesis: Aging in the F344/N X BN RAT rat heart will be associated with
alterations in DGC function.
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Chapter 2
Review of the Literature
A review of the pertinent literature concerning the present study will be presented
in the following chapter. The following areas will be addressed: 1) Age associated
alterations in cardiac muscle and 2) Structure and function of dystrophin glycoprotein
complex.

Age associated alterations in cardiac muscle
The aged (65+ years of age) now comprise the most rapidly growing segment of
the United States and cardiovascular disease(CVD) is the leading cause of death in this
population [16]. The occurrence, severity, and prognosis of CVD may reflect ageassociated changes in cardiovascular structure and function [17]. In humans, information
as to how aging affects factors that regulate intrinsic myocardial contractility is
incomplete, because the effectiveness of intrinsic myocardial contractility in the intact
circulation is difficult to separate from the effects of ventricular preload and afterload or
from autonomic modulatory influences on contractility. Nonetheless, a deficit in maximal
intrinsic contractility of older persons might be expected on the basis of the reduced
maximum heart rate, as the heart rate, per se, is a determinant of the myocardial
contractile state [1]. Olivetti et al., (1991) examined the effects of aging on the human
myocardium in 67 hearts obtained from individuals between the ages of 17-90 years who
died from causes other than cardiovascular disease. Regression analysis of their results
demonstrated that the aging process was characterized by a loss of 38 million and 14
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million myocyte nuclei/yr in the left and right ventricular myocardium, respectively [18].
In another study Melissari et al., (1991) measured cardiac dimensions with respect to
body weight, and the number of myocyte nuclei in the ventricle of 45 males and 22
females (17 to 90 years old), who died from causes independent of cardiovascular
disease. These researchers found that with aging, total heart weight increased slightly,
while left ventricular and interventricular septum weights decreased significantly (r =
0.44; P < 0.001). At the structural level the number of myocyte nuclei within the left
ventricle (LV) decreased (r = 0.45; P< 0.001), whereas myocyte cell volume per nucleus
increased (r = 0.30; P >0.05) with age [19]. Taken together these data suggested that
advancing age is associated with increase in heart mass, and left ventricular hypertrophy
due to an increase in the size of cardiac myocytes [18, 20].
Gerstenblith et al., (1977) performed echocardiograms on 105 male participants in
the NIA volunteer Longitudinal Study Program and their findings suggest that aging in
the normal male is associated with altered left ventricular diastolic filling, increased aortic
root diameter and LV hypertrophy but little change in contractile ability in the resting
state [21]. Using 2-dimensional echocardiograms, Downes et al., (1989) studied the effect
of aging on the pattern of LV diastolic filling in 11 elderly subjects (68 ± 5 years, mean ±
standard deviation) and 15 normal young adults (31 ± 7 years) without coronary artery
disease, systemic hypertension, LV hypertrophy or abnormality of LV systolic function.
The data suggested that early diastolic filling is reduced in normal aged subjects, even in
the absence of coronary artery disease and systolic dysfunction [22]. Morales et al.,
(2000) performed quantitative echocardiography in seventy-eight subjects (47 men; mean
age, 51 years; age range, 23-87 years) without apparent cardiovascular and systemic
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disease and revealed that advancing age is associated with changes in myocardial
structure that are characterized by a greater echogenicity and loss in tonal organization,
possibly due to increased collagen content within the fibers [23]. Taken together, these
data suggest that cardiac aging in humans is characterized by alterations in left
ventricular diastolic filling, ventricular dimensions, diastolic function and increased
incidence of arrthymias.
Cardiac structure and function are remarkably similar among mammalian species,
and the use of animal models has been extremely helpful in developing treatment
strategies for alleviating heart disease in humans. Extending animal studies beyond young
adult ages to very old ages may provide similar benefits to cardiovascular health of the
growing aged population. The pathophysiology of age-related cardiac dysfunction has
been mostly studied in human hearts at the time of transplantation while animal models
have been found to be extremely useful for the assessment of pathological processes and
the development of new treatments [24, 25]. The Fischer 344/Brown Norway F1 (F344/N
X BN) rat is recommended for age-related studies by the NIA because this hybrid rat
lives longer and has a lower rate of pathological conditions than inbred rats [4]. Ageassociated changes in cellular mechanisms of cardiac function include cardiac myocyte
enlargement and coordinated changes in gene expression. These changes modify several
key steps of cardiac muscle excitation-Ca+2 release-contraction relaxation coupling,
resulting in a prolonged action potential, a prolonged cytosolic Ca+2 transient and a
prolonged contraction and delayed relaxation [26].

Hacker et al.,(2006)

used

echocardiographic and hemodynamic analyses to determine standard values for LV mass,
LV wall thickness, LV chamber diameter, heart rate, LV fractional shortening, mitral
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inflow velocity, LV relaxation time, and aortic/LV pressures in male F344/N X BN rats
from adulthood to the very aged (n = 6 per 12-, 18-, 21-, 24-, 27-, 30-, 33-, 36-, and 39mo-old group). Their data suggested that aged rats had an increased LV mass-to-body
weight ratio and deteriorated systolic function. Using histological analysis they
demonstrated a gradual increase in fibrosis and a decrease in cardiomyocyte volume
density with age [27].
More recently, Walker et al., (2006) performed two-dimensional ECHO
measurements, two-dimensional guided M-mode, Doppler M-mode, and other recordings
from parasternal long- and short-axis views on male F344/N X BN rats aged 6-, 30-, and
36-month and revealed persistent cardiac arrhythmias in 72% (13/18) of 36-month rats,
10% of (1/10) of 30-month rats and none in 6-month rats . Gross and microscopic studies
revealed left ventricular (LV) dilatation, borderline to mild hypertrophy, and areas of
fibrosis that were common in 36-mo rats, less evident in 30-mo rats, and absent in 6-mo
rats [4]. These results suggested that advancing age in F344/N X BN rats is associated
with declines in cardiac function (diastolic and systolic indices), LV structural changes
(chamber dimensions, volumes, and wall thicknesses), and persistent arrhythmias. Taken
together these data suggest that aging in the F344/N X BN rats, like humans, is associated
with alterations in cardiac structure and function. To our knowledge, the molecular
mechanism(s) responsible for mediating the age-associated phenotypic changes in the
F344/N X BN rat heart have not been investigated.
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Summary
Similar to humans, advancing age in the F344/N X BN rats appears to be
associated with increase in heart mass, left ventricular hypertrophy due to an increase in
the size of cardiac myocytes accompanied by focal increase in collagen, increased
incidence of cardiac arrhythmias, decrease in ventricular compliance and impairements in
systolic and diastolic function. To our knowledge, the molecular events which may
mediate age-associated changes in the F344/N X BN rat heart have not been investigated.
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Structure and function of dystrophin glycoprotein complex
The identification of dystrophin [28] and the subsequent characterization of the
dystrophin glycoprotein complex (DGC), [6, 7] was a major breAKThrough in
understanding the molecular pathogenesis of muscular dystrophy. The DGC is a
specialization of cardiac and skeletal muscle membrane, which has both mechanical
stabilizing and signaling roles in mediating interactions between the cytoskeleton,
membrane, and extracellular matrix. Known components of the DGC include dystrophin,
sarcoglycans, dystroglycan, dystrobrevins, syntrophins, sarcospan, caveolin-3, and NO
synthase [29].
The dystrophin isoform in cardiac and skeletal muscle is 427 kDa and is thought
to function largely as a structural molecule although it is also the target of a variety of
kinases, including calmodulin-dependent protein kinase II, [30, 31], p44 ERK1 mitogenactivated protein kinase (MAPK) [37] p34 cdc2 kinase, [32] and casein kinase [33].
Dystrophin has been found to be phosphorylated both in vivo [33] and in vitro [32, 34],
however, the physiological significance of these events has yet to be determined.
Assembly of the DGC is dependent on specific domains of the dystrophin protein,
and accordingly, the DGC is absent from the sarcolemma of dystrophin deficient muscle
[35].

Danialou et al., (2001) using normal and dystrophin deficient (mdx) mice models

reported that cardiomyocytes lacking dystrophin are abnormally vulnerable to mechanical
stress-induced injury, thereby resulting in a loss of sarcolemmal integrity and attendant
contractile dysfunction [9]. Kamogawa et al., (2001) using aortic banding to induce
cardiac hypertrophy in 12-week-old mdx and control mice and demonstrated that mdx
mice showed increased vulnerability to acute pressure overload as characterized by
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increased focal lesions in the left ventricular wall, damaged myocytes, increased
inflammatory cells, and fibrosis [36]. Taken together, these results suggest that the
primary function of dystrophin is to provide mechanical reinforcement to the sarcolemma
[37].
The signaling mechanism(s) associated with the DGC function that might
mediate cell death are not fully understood. β-dystroglycan is a transmembrane protein
that binds to dystrophin or utrophin in the cytoplasm and to other proteins that have
demonstrated roles in signal transduction including growth factor receptor binding
protein 2 (Grb2) and focal adhension kinase (FAK) [38-44]. Both FAK and Grb2
function as mediators of survival signaling in numerous cell types, often working through
PI3K and the downstream effector of PI3K, AKT, (protein kinase B) a serine/threonine
kinase [45]. How PI3K and AKT may function in cell death is not clear however, it is
thought that cell adhesion to the extracellular matrix activates lipid-associated PI3K, [46,
47] which in turn induces translocation of AKT from the cytoplasmic pool to the cell
membrane, where it is activated by phosphorylation [48]. The PI3K/AKT pathway
promotes survival in a wide variety of cells [48, 49]. Using a blocking antibody directed
against α-dystroglycan, Langenbach.,et al, (2002) showed that disruption of dystroglycan
interactions with laminin induces apoptosis in myotube cultures due to impaired signaling
through the PI3K/AKT pathway. In the same study, a pharmacological inhibitor of PI3K
yielded decreased phosphorylation of AKT and its downstream effector, glycogen
synthase kinase (GSK)-3β and induced apoptosis in muscle cell cultures. Together these
results support a role for the PI3K/AKT pathway in the propagation of cell-survival
signals mediated by the DGC [50].
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The sarcoglycans are a family of homologous transmembrane proteins with single
membrane spanning domains [51]. Several studies of the sarcoglycan complex have
suggested that β- and δ-sarcoglycans are the most tightly associated and form a functional
core of the complex [52, 53]. It is thought that the sarcoglycan complex is necessary for
“stabilization” of the DGC in general and the dystrophin–dystroglycan interaction in
particular [52, 53]. The association of the DGC with focal adhesion proteins such as b1and b3-integrins, vinculin, and FAK is modulated by α-sarcoglycan expression
suggesting perhaps that the sarcoglycans may also be involved in cell signaling [54].
Further studies examining the role of the sarcoglycans and the DGC using ex vivo models
of muscle loading and contraction will be invaluable to furthering our understanding of
DGC function and structure.

Summary
The dystrophin glycoprotein complex forms a strong mechanical link between the
cytoskeleton and extracellular matrix, and several proteins of the DGC also participate in
signaling cascades. The signal transduction cascades associated with the DGC , like those
associated with integrins and caveolins, play important roles in cell survival signaling,
cellular defence mechanisms, and regulation of the balance between cell survival and cell
death. The biochemical mechanisms by which the alterations in DGC lead to cell death
remain elusive. To our knowledge, the regulation of DGC with advancing age has not
been investigated.
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Abstract
It is estimated that by 2053, nearly one in four individuals in the United States will be
sixty-five years of age or older. Advancing age in humans and in the F344/N X BN rat is
associated with alteration in cardiac morphology and impaired function. Recent data has
suggested that disruption of the dystrophin-glycoprotein complex (DGC) may be
involved in mediating the progression of cardiac hypertrophy and failure. Whether
alterations in the DGC may mediate age-associated cardiac dysfunction is not known.
Here we examined the regulation of DGC proteins in the hearts of adult (6 months), aged
(30 months), and very aged (36 months) F344/N X BN rats . The dystrophin content of
very aged hearts was 43.66 ± 7.87% lower compared to aged animals, while αdystroglycan and β-dystroglycan were 6.93 ± 5.16% and 58.36 ± 3.64% higher,
respectively (P < 0.05) compared to young adult animals. Similar changes were seen in
the sarcoglycan proteins, where aging appeared to diminish the α-sarcoglycan, βsarcoglycan and δ-sarcoglycan content by 13.89 ± 3.1%,15.8 ± 2.8% and 18.63 ± 3.04%,
respectively (P < 0.05).

Immunohistochemical analysis confirmed these data and

demonstrated qualitative differences in localization of the DGC molecules. These
alterations in the DGC occurred coincident with age-associated increases in cytoplasmic
anti-rat IgG immunoreactivity, TUNEL positive nuclei, the proteolytic cleavage of αfodrin, diminished AKT phosphoryation (Ser 308) and evidence of caspase-3 but not
caspase-12 activity. These data suggest that the aging in the F344/N X BN rat heart is
associated with differences in the composition of the DGC and further, that alterations in
the DGC may be associated with age-associated cardiac remodeling and cardiomyocyte
death.
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Introduction
Senesecence is associated with a progressive impairment of cardiac function,
including stroke volume, ejection fraction, and cardiac output [55]. Structural changes in
the aging heart include cardiomyocyte cell loss and reactive hypertrophy of the remaining
cells [56, 57]. The factors regulating these alterations are not well understood. The
pathophysiology of age-related cardiac dysfunction has been mostly studied in human
hearts at the time of transplantation while animal models have been found to be
extremely useful for the assessment of pathological processes and the development of
new treatments [24, 25]. Using the Fischer 344 x Brown Norway F1 hybrid rat (F344/N
X BN rat ), an aging model particularly suited for the study of age-related
pathophysiology [24, 25, 58]. we and others have recently demonstrated that aging in the
F344/N X BN rats is associated with increases in heart mass, left ventricular hypertrophy,
increased incidence of cardiac arrhythmias, decreases in ventricular compliance and
impairments in systolic and diastolic function [27]. The precise mechanism responsible
for these changes is unknown.
The dystrophin-glycoprotein complex (DGC) is thought to provide a strong
mechanical link from the intracellular cytoskeleton to the extracellular matrix. Known
components of the DGC include dystrophin, dystroglycans, sarcoglycans, integrins,
caveolin-3 and others, with the expression of these proteins differing depending on
muscle type [59]. Recent data have suggested that disruption of the DGC may be
involved in mediating the progression of cardiac hypertrophy and failure. For example,
mutation of genes encoding proteins in the DGC can cause cardiomyopathy, while the
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disordered accumulation of DGC proteins may lead to contractile dysfunction [60, 61].
Selective loss of dystrophin in patients with Duchenne muscular dystrophy and mdx mice
has been shown to increase the susceptibility of cardiac myocytes to load-induced
damage while mutations in the gene encoding dystrophin, which abolish or diminish its
expression or which truncate the protein product, cause dilated cardiomyopathy and are
thought to be involved in development of arrhythmias [62-65].
Although the proteins of specific compartments of the DGC are well described,
little is known about their regulation in non-dystrophic muscle.

Moreover, to our

knowledge, how aging affects the DGC in cardiomyocytes has not been investigated. As
aging and the dystrophies exhibit similar impacts on cardiac morphology and function,
we hypothesized that aging would alter the expression and localization of DGC proteins
in the cardiomyocytes. The findings of such alterations, if present, would be important as
this information may provide insight regarding the mechanisms underlying ageassociated cardiac dysfunction.
In the present study, we examined the effects of aging on the relative content of
several proteins belonging to the DGC in the hearts of F344/N X BN rats. Our data
suggest that aging alters the regulation of DGC proteins and that this regulation is similar
to that observed during myocardial infarction.

Although it is likely that dissimilar

mechanism(s) underlie the cardiac dysfunction seen in aging and the muscular
dystrophies our data are consistent with the notion that both conditions are associated
with alterations in the DGC.
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MATERAIALS AND METHODS
Animals
Animal care and procedures were conducted in accordance with the Animal Use
Review Board of Marshall University using the criteria outlined by the American
Association of Laboratory Animal Care as proclaimed in the Animal Welfare Act (PL89544, PL91-979, and PL94-279). Adult (6 months, n=12), aged (30 months, n=12), and
very aged (36 months, n=12) male F344/N X BN rats were obtained from the National
Institute on Aging. Rats were housed two per cage in an AALAC approved vivarium.
Housing conditions consisted of a 12H:12H dark-light cycle with temperature maintained
at 22 ± 2° C. Animals were provided food and water ad libitum. Rats were allowed to
recover from shipment for at least two weeks before experimentation began. During this
time the animals were carefully observed and weighed weekly. None of the animals
exhibited signs of failure to thrive, such as precipitous weight loss, disinterest in the
environment, or unexpected gait alterations.

Materials
Antibodies used were dystrophin (dys-2) from Novacastro (Ontario, Canda); αdystroglycan (VIA4-1) from Upstate (Charlottesville, VA); β –dystroglycan (sc16165),
β –Sarcoglycan (sc 28279), δ –Sarcoglycan (sc28281) from Santa Cruz (Santa Cruz, CA);
α-sarcoglycan (VP-A105) from Vector Laboratories (Burlingame, CA); and rat IgG
antibody (T6392) from Molecular Probes (Eugene, OR). Caspase 3, Caspase 9, Caspase
12, α-fodrin, AKT, Thr308 phosphorylated AKT, BAD, Ser112 phosphorylated BAD,
Ser136 phophorylated BAD, XIAP antibodies and Rabbit and mouse IgG secondary
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antibodies were purchased from Cell Signaling Technology (Beverly, MA). In Situ Cell
Death Detection Kit, Fluorescein (TUNEL) was from Roche Diagnostics (Mannheim,
Germany). Precast 10% SDS-PAGE gels were procured from Cambrex Biosciences
(Baltimore, MD), and enhanced chemiluminescence (ECL) western blotting detection
reagent was from Amersham Biosciences (Piscataway, NJ).

Restore western

blot

stripping buffer was obtained from Pierce (Rockford, IL) 3T3 and L6 cell lysates were
from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were purchased
from Sigma (St. Louis, MO).

Determination of DGC protein content
Animals were anesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg ip)
and supplemented as necessary for reflexive response [58].

Hearts were quickly

removed, blotted dry, weighed, and immediately frozen in liquid nitrogen. Tissues were
stored at -80° C until use. For the preparation of protein isolates, heart tissues were
pulverized in liquid nitrogen using a mortar and pestle and washed three times with ice
cold phosphate buffered saline (PBS). Proteins were extracted by incubating samples on
ice in 10 μl/mg of modified RIPA Buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 0.25%
Na-deoxycholate, 1 mM EDTA, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin,
1 mM PMSF, 1 mM Na3VO4, 1 mM NaF) and centrifugation for 10 min at 800 * g. After
removing the supernatant, pellets were re-extracted twice and then washed three times
with ice cold PBS. Membrane proteins were obtained by resuspending the pellets (1ml/g)
in a buffer containing 1% deoxycholate, 1% NP-40, 10 mM NaPO4, 140 mM NaCl, and 2
mM EDTA supplemented with100 mM NaF, 1 mM Na3VO4, 2 mM PMSF 1 μg/ml
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aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin. After collecting the supernatant by
centrifugation for 10 min 800 * g, protein concentration was determined in triplicate via
the Bradford method (Pierce) using bovine serum albumin as a standard. Samples were
boiled and analyzed using 7.5% or 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). To allow direct comparisons to be made between age
groups, samples from different age groups were run on the same gel.

Following

electrophoresis, protein was transferred onto Hybond nitrocellulose membranes
(Amersham Biosciences, Piscataway, NJ) using standard conditions [66] and stained with
Ponceau S (data not shown) to confirm successful transfer of proteins and equal loading
of lanes. Membranes were blocked in tris buffered saline (TBS) with 0.5% Tween-20
(TBS-T) and 5% milk for 1 hr at room temperature, washed (TBST, 3 * 5 min), and
incubated in primary antibody overnight at 4ºC or 1 hr at room temperature as outlined by
the antibody manufacturer. After washing(TBST, 3 * 5 min), membranes were incubated
in horseradish peroxidase (HRP)-linked secondary antibodies for 1 hr at room
temperature, washed (TBS-T, 3 * 5 min) and the protein bands visualized by enhanced
chemiluminescence (ECL) Western blotting detection reagent (Amersham Biosciences,
Piscataway, NJ). Bands were quantified by densitometry (Epson Perfection 3200 PHOTO
scanner) and Imaging software (AlphaEaseFC).

Exposure time was adjusted to keep the

integrated optical densities within a linear and nonsaturated range. Specificity of the
bands was assessed using Dual Color molecular-weight markers (Pierce), a biotinylated
protein ladder (Pierce), and NIH 3T3 or L6 cell lysates (Cell Signaling) positive controls.
Immunoblots were stripped with Restore western blot stripping buffer as detailed by the
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manufacturer. After verifying the absence of residual antibody binding by interrogating
the membrane with the ECL reagent, membranes were washed and reprobed.

Histological imaging and immunohistochemistry
Hearts were sectioned (8 μm) using an IEC Minotome cryostat and collected on
poly-lysine (Sigma, St. Louis, MO) coated slides. After fixing in acetone (-20°C for 2
min), sections were stained with hematoxylin and eosin and mounted for the evaluation
of cardiac morphology. Immunostaining for dystrophin, rat IgG, α-dystroglycan, βdystroglycan, and α-sarcoglycan was visualized by immunofluorescence as outlined by
the antibody manufacturer. Briefly, sections were incubated for 30 min in a blocking
solution (5% bovine serum albumin (BSA) and PBS containing 0.5% Tween 20 (PBS-T,
pH 7.5) and then incubated with specific antisera diluted in PSB-T (anti-dystrophin
1:100, α-dystroglycan 1:100, β-dystroglycan 1:100, α-sarcoglycan 1:100, rat-IgG 1:100)
for 1 hr at 37˚C in a humidified chamber. After washing in PBST (3 * 5 min), sections
were incubated with the appropriate FITC or Texas RED labeled secondary antibody
(1:200) if appropriate, for 1 hr at 37˚C in a humidified chamber. After mounting,
specimens were visualized by epifluorescence using an Olympus fluorescence
microscope (Melville, NY) fitted with a 40X objective or on a Nikon Diaphot microscope
for confocal analysis. Confocal imaging was performed using a BioRad MRC 1024
scanning system using the 488 nm line from a krypton/argon laser for flourophore
excitation. Emissions were collected through either 515 nm long pass or 522/532 nm
band pass filters.

To allow approximate quantitative comparisons, all imaging
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parameters (pixel dwell time, optical and electronic filters, confocal iris, laser power, and
detector gain and offset) were kept constant between samples.

TUNEL Staining
Tissue sections (8 μm) obtained from 6- (n=3), 30- (n=3), and 36- (n=3) month
hearts were fixed with 4% paraformaldehyde, washed with PBS (pH 7.4), and then
permeabilized with 0.1% sodium citrate and 0.1% Triton X. DNA fragmentation was
determined by TdT-mediated dUTP nick end labeling (TUNEL) as suggested by the
manufacturer’s recommendations. Cross-sections from each muscle were treated with
DNase I to induce DNA fragmentation as a positive control. Three randomly selected
regions from each cross section were visualized by epifluorescence using an Olympus
fluorescence microscope (Melville, NY) fitted with a 20X objective.

Images were

recorded digitally using a CCD camera (Olympus, Melville, NY), and the samples were
analyzed by counting positively stained nuclei.

Data Analysis
Results are presented as mean ± SEM. Data were analyzed using SigmaStat 3.5.
A one-way analysis of variance (ANOVA) was performed for overall comparisons with
the Student-Newman-Keuls post hoc test used to determine differences between groups.
The level of significance accepted a priori was P≤ 0.05.
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RESULTS
Aging in the F344/N X BN rat heart is associated with alterations in the cardiac
DGC
Compared to young adults (6 mo), heart mass was 88.54 ± 8.38% and 72.9 ±
6.98% higher in 30- and 36-month old animals, respectively (P < 0.05) (Table 1).
Immunoblots of protein isolates obtained from the membrane fraction of adult, aged and
very aged hearts were examined for the relative abundance of dystrophin as outlined
previously [67]. Compared to 6 month animals, the amount of dystrophin was 52.9 ±
2.49% higher (P < 0.05) and unchanged in 30- and 36-month hearts, respectively
(Fig.1A). To assess the subcellular distribution of dystrophin, heart cross sections were
examined by immunohistochemical analysis. Immunoflourescent antibodies against the
carboxy terminus of dystrophin in the 6-month heart muscles showed uniform
immunoreactivity, predominantly along the membranes of the myocytes (Fig.1B). The
dystrophin immunoreactivity along the membranes of very aged heart fibers appeared
irregular with patches of intense fluorescence. With aging, the dystrophin
immunoreactivity often appears to be discontinuous and was at times completely abscent
along the sarcolemma of cardiac muscle fibres (Fig. 1C) of very aged hearts. Together,
these data suggest that dystrophin content and localization are altered with aging.
Because alterations in the amount of dystrophin may influence the composition of
the DGC, we examined whether aging may affect the amount of membrane associated
dystroglycans and sarcoglycans. Immunoblot analysis showed that the amount of αdystroglycan was unchanged in the 30-month hearts while it was 6.93 ± 5.16% higher in
hearts from 36- compared to 6-month animals (P < 0.05; Fig. 2A). Immunohistochemical
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comparisons revealed more diffuse α-dystroglycan immunoreactivity in the cytosol in the
36-month hearts cross sections (Fig. 2B) as compared to 6-month hearts where αdystroglycan immunoreactivity was predominantly membrane associated (Fig. 2C). This
suggests that aging may be associated with alterations in the amount of α-dystroglycan
appropriately targeted to the cell membrane.
Compared to 6-month animals, the amount of β-dystroglycan was unchanged and
58.36 ± 3.64%, higher (P < 0.05) in 30- and 36-month hearts, respectively (Fig. 2D).
Supporting these data, immunofluorescence findings demonstrated that the amount of
membrane associated β-dystroglycan appeared to be altered with aging. Six-month hearts
showed smooth and well-defined membrane, bordering each myofiber (Fig. 2E), whereas
in 36-month hearts the β-dystroglycan immunoreactive signal was more intense and
diffuse (Fig. 2F).
Conversely, the content of α-sarcoglycan was found to be slightly, yet
significantly lower in 30- (8.47 ± 2.6%) and 36-month (13.89 ± 3.1%) hearts as compared
to 6-month hearts (Fig. 3A; P < 0.05). As opposed to the well defined immunoreactive
signal in 6-month hearts ( Fig. 3B), with aging, the α-sarcoglycan immunohistochemical
staining in 36-month hearts appears, microscopically, as a broad band at the sarcolemma
with occasional whispy extensions into the proximal sarcoplasm (Fig. 3C). Similar to α–
sarcoglycan, with aging, the amount of β-sarcoglycan and δ-sarcoglycan in 30- and 36month hearts was significantly lower by 11.85 ± 3.35% and 15.8 ± 2.8%, and 27.62 ±
2.41% and 18.63 ± 3.04%, respectively, (P < 0.05; Figs. 4A, 4B).

-22-

Alterations in membrane dystrophin content are associated with changes in cardiac
myofibre membrane stability
Because the DGC is thought to play a pivotal role in stabilizing the muscle cell
membrane we examined whether age-associated alterations in the DGC complex were
associated with alterations in membrane permeability. To test this possibility, we
examined tissue sections obtained from adult, aged and very aged rat hearts for the
presence of IgG (150 kDa), a serum protein that is normally excluded from entry into the
muscle fiber. No evidence of IgG immunoreactivity was demonstrated in the cytosol of
cardiac muscle fibres obtained from 6-month rats (Fig. 5A). In contrast, with aging
positive staining with anti-rat IgG antibodies was observed in the cytoplasm of cardiac
myofibres obtained from 30-month (Fig. 5B) and 36-month rats (Fig. 5C).

Taken

together, these data suggest that aging in the F344/N X BN rat heart is associated with
alterations in myocyte permeability.

Aging in the F344/N X BN rat heart is associated with increased TUNEL positive
staining and casapase-3 activation
It is well established that alterations in membrane permeability are associated
with cellular apoptosis [68]. To examine whether age-related changes in IgG permeability
are related to myocyte apoptosis we examined the number of nuclei staining positively
for DNA fragmentation by TUNEL staining. Compared to 6-month hearts, the number of
TUNEL positive nuclei increased by ~ 29 and ~ 48 fold in 30-and 36-month hearts,
respectively (P < 0.05; Fig. 6).
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A critical step in the execution of the apoptotic program eliciting DNA
fragmentation is cleavage of caspase-3 into 19- and 17- kDa fragments [69]. Caspases are
cysteine-dependent aspartate specific proteases functioning as endonucleases integral in
the final execution of nuclei and cell death [69, 70]. With aging the amount of the full
length (inactive) caspase 3 was 38.26 ± 4.09% higher in the 30 month hearts, while it is
9.69 ± 4% lower in the 36-month hearts as compared to the 6 month hearts (Fig. 7C) (P <
0.05). Caspase-3 activation as measured by densitometric analysis of the cleaved 17 kDa
caspase-3 fragment content, was markedly higher in the 36month hearts (138.2 ±
34.36%) as compared to 6-month hearts, with no significant difference between the 6month and 30-month hearts (Fig. 7A). The content of the 19 kDa cleaved caspase-3
fragment was 32.28 ± 2.43% and 192.4 ± 15.6% higher in the 30- and 36-month hearts as
compared to the 6 month hearts (Fig. 7B; P < 0.05). To examine the upstream signaling
events responsible for the activation of caspase-3, we investigated the regulation of
caspases-9 and -12 with aging. Caspase-9 is activated via mitochondrial cytochrome C
release and is thought to activate caspase-3, while caspase-12 signals the endoplasmic
reticulum / sarcoplasmic reticulum (ER/SR) stress induced apoptosis [71]. The content of
38 kDa fragment of procaspase-9 was 13.2 ± 3.36% lower in 30-month hearts and 6.45 ±
2.68% higher in 36-month hearts compared to 6-month hearts (Fig. 8A). The 40 kDa
fragment of caspase-9 was higher (34.83 ± 9.32) in 36-month hearts (P < 0.05) with no
significant difference between 6-and 30-month hearts (Fig. 8B). In a similar fashion, the
amount of full length caspase-9 was 31.23 ± 11.73% higher in 36-month hearts (P < 0.05)
with no significant difference in 30-month hearts compared to 6-month hearts (Fig. 8C).
No evidence of caspase-12 cleavage was detectable.
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As a means of further verifying the activation of caspase-3 we examined the
effects of aging on the cleavage of α-fodrin, a cytoskeletal protein which undergoes
caspase dependent proteolytic processing in many types of cell death [72] but has not, to
our knowledge, been studied in aging cardiac muscle. The content of α-fodrin was (13.65
± 1.71%) lower in 30-month hearts and unchanged in 36-month, compared to 6-month
hearts (Fig. 9A). The full length 240 kDa α-fodrin protein can be cleaved at several sites
within its sequence by activated calpains to yield an N-terminal fragment of 150 kDa or
caspases yielding a C-terminal 120 kDa product [73, 74]. Compared to hearts obtained
from 6-month animals, the amount of the caspase dependent form of α-fodrin cleavage
was 23.84 ± 4.3% lower (P < 0.05) in 30-month hearts and 16.52 ± 1.2% higher (P <
0.05) in 36-month (Fig. 9B). The calpain-dependent (150kDa) fragment of α-fodrin
cleavage was undetectable. Taken together these data suggest that aging in the F344/N X
BN rat heart is association with increased caspase-3 but not caspase-12 activation.

The regulation of anti- and pro-apoptotic regulators with Aging in the F344/N X BN
rat

heart is associated with alterations in AKT phosphorylation and AKT-

associated signaling
AKT/PKB is a serine/threonine protein kinase that functions as a critical
regulator of cell survival and proliferation [75]. The content of AKT was 27.97 ± 2.28%
and 14.05 ± 2.06% lower (P < 0.05) in 30-and 36-month hearts compared to 6-month
hearts (Fig. 10A). In a similar fashion, compared to that seen in the hearts obtained from
6-month animals, the amount of AKT phosphorylation (Thr 308) was 24.15 ± 3.2% and
25.66 ± 2.12% lower (P < 0.05) in the 30- and 36-month hearts, respectively (Fig. 10B).
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Although not fully understood, it is thought that AKT may exert some of its antiapoptotic functions through its ability to affect the activity of other anti-apoptotic proteins
such as BAD and X chromosome-linked inhibitor of apoptosis protein (XIAP) [76-78].
To further explore how age-related changes in AKT regulation and apoptosis may be
linked we examined how aging may alter the regulation of BAD and XIAP. Compared to
6-month cardiac isolates, the amount of BAD in 30- and 36-month hearts was 39.08 ±
10.99% and 40.41 ± 8.7% higher (P < 0.05; Fig. 11A). In a similar fashion, the AKTdependent form of phosphorylated BAD (Ser 112) was 103.73 ± 3.37% higher (P < 0.05)
in 30- than 6-month hearts (Fig. 11B) while compared to 6-month hearts, the
phosphorylation of BAD at Ser 136 was 74.95 ± 8.04% higher (P < 0.05) in samples
obtained from 36-month old animals (Fig. 11C). In a similar fashion, XIAP, an
antiapoptotic protein thought to inhibit caspase-3, was 122.86 ± 16.34% and 148.57 ±
3.02% higher in 30-and 36-month hearts compared to 6-month hearts (Fig. 12). Taken
together these data suggest that aging in the F344/N X BN rat is associated with changes
in the levels of AKT phosphorylation and AKT-associated signaling.
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Discussion
Increasing age is thought to be the major risk factor for cardiovascular disease [1].
In otherwise healthy persons and rats, the aging heart is characterized by increased left
ventricular wall thickness and chamber diameter, increased mass and reduced diastolic
function [57].

The cellular mechanism(s) responsible for these structural and

physiological alterations remain largely unexplained. Similarly, how aging may affect
the molecular organization or function of the cardiac myocyte has remained elusive. In
present investigation we examined how aging may effect the protein composition of the
DGC in the hearts of F344/N X BN rats, an animal model considered by many as
particularly appropriate for the investigation of gerontological phenomena [79]. Our
findings suggest that aging in the F344/N X BN heart is associated with alterations in
DGC-related protein content and localization.

The regulation of DGC proteins is altered in the aging F344/N X BN rat heart.
Alterations to the muscle DGC and how these changes may influence muscle
morphology or function have been well examined in the muscular dystrophies [80, 81].
Similarly, it is known that the Duchenne and Becker muscular dystrophies, are associated
with high incidence of dilated cardiomyopathy [62, 82], and that dystrophin mutations are
a cause of X-linked dilated cardiomyopathy [64, 83], suggesting perhaps that disruption
of the dystrophin–glycoprotein complex may be associated with cardiac dysfunction [84].
Less understood however, is how the DGC of cardiac muscle is regulated or how aging
may affect this complex in the absence of disease. One of the main findings of the
present study is that aging in the F344/N X BN rat heart appears to be associated with
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alterations to both the dystroglycan (Fig. 2) and sarcoglycan (Fig. 3) complexes. The
regulation of these complexes appears to occur in a diametric fashion. For example, while
β-dystroglycan protein levels increase with aging, the amount of α-, β- and γ-sarcoglycan
decrease. It has been hypothesized that β-dystroglycan acts as a link between proteins in
the DGC complex and the extracellular matrix [5] as such, we feel it likely that the ageassociated upregulation of β-dystroglycan we detect may represent an adaptive response
of cardiomyocyte to “reestablish” functional connection between the cell cytoskeleton
and the extracellular matrix. Further experiments using other time points within the
aging spectrum will no doubt be useful in determining if this situation is indeed
occurring.
Although the complete function of the DGC has not been determined, it is thought
that the primary function of the DCG is to regulate the structural stability of the muscle
cell membrane. Indeed, in the presence of altered dystroglycan or sarcoglycan levels, it
has been shown that the muscle membrane is destabilized [85, 86]. This destabilization of
the membrane in turn, is associated with increased cell apoptosis [50, 87]. Our findings
that aging in the F344/N X BN rat heart is associated with increases in membrane
permeability (Fig. 5) and TUNEL positive cells (Fig. 6) are consistent with the possibility
that alterations in the aging cardiac DGC are associated with membrane stability and
increased cell apoptosis. Future studies perhaps using in vitro models will be useful at
further substantiating this premise.
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Alterations in DGC regulation in the aging F344/N X BN rat heart are associated
with increased caspase activation.
Remodeling of the aging heart typically involves a large net loss of active cardiac
myocytes (≥ 30%) and reactive hypertrophy of the remaining cells [88-91]. The
mechanism(s) which mediate these age-related decreases in myocyte number are not fully
understood but recent data suggest that apoptosis may be involved [92, 93]. One of the
major apoptotic signaling pathways includes the mitochondrial-driven pathway [94]. Two
of the key effectors of the mitochondrial-mediated pathway are the endopeptidases,
caspase-9 and caspase-3 [95, 96].

In this pathway, it is postulated that cytosolic

cyotochrome c couples with apoptotic protease activating factor-1 (Apaf-1) which in turn,
binds caspase-9. Auto cleavage of caspase-9 results in the formation of the complete
‘‘apoptosome’’ (Apaf-1, adenosine triphosphate, cytochrome c) that cleaves and activates
procaspase-3 [70]. Active caspase-3 in turn, is thought to initiate other capases resulting
in proteolytic disassembly of the cell [96]. To examine the mechanism of age-related
DNA strand breakage in the aging rat heart we first investigated how aging effected the
expression and activation of caspase-3 and -9. Because caspases are normally activated
by proteolytic cleavage [97], we examined the effects of aging on the amount of fulllength versus cleaved caspase-3 in the F344/N X BN rat heart. With aging in the rat heart
we found alterations in the level of cleaved caspase-3 and in the amount of its upstream
activator, caspase-9, (Figs. 7 and 8). As a means of further investigating the possibility of
caspase-3 activation, we used immunoblotting as a measure to determine calpaindependent proteolysis of α-fodrin [72]. Consistent with our caspase-3 data, with aging
we observed a significant increase in the amount of caspase-cleaved α-fodrin (Fig. 9).
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Taken together, these data suggest that the mitochondrial-mediated apoptosis may play a
significant role in mediating age-related cardiac apoptosis. Similar findings with regards
to the possibility that these caspases may be involved in cardiac remodeling during aging
have been reported previously [92, 93].
Similar to the mitochondria, the endoplasmic reticulum / sarcoplasmic reticulum
(ER/SR) may also be involved in mediating cell apoptosis. In this instance, it is thought
that cellular stress may cause calcium influx into the cytoplasm from the extracellular
environment and from the ER or SR through the cell membrane and the ER/SR channels,
respectively [98]. Given the key role that the ER/SR plays in regulating cardiac calcium
homeostasis and the synthesis of secretary proteins such as atrial natriuretic peptide in the
heart, the possibility exists that dysfunction of the ER might thus contribute to the
pathogenesis of heart disease [99]. Although not fully understood, it is thought that
caspase-12 plays an important role in the process of cell death caused by ER stress [100].
To our knowledge, the possibility that ER/SR stress may play a role in the aging heart has
not been investigated. With aging we failed to detect any evidence of caspase-12
activation (Fig. 13) suggesting that SR/ER stress is not the primary cause of age-related
apoptosis in the aging F344/N X BN rat heart.

Alterations in DGC regulation in the aging F344/N X BN rat heart are associated
with decreased AKT phosphorylation.
In addition to the caspases which are thought to be pro-apoptotic, it is possible
that age-related changes in the heart DGC could be associated with decreases in antiapoptotic signaling. For example, inhibition of α-dystroglycan binding to laminin-2 has
been found to be associated with diminished phosphorylation of protein kinase B (AKT)
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and induction of apoptosis in muscle cell cultures [50]. In the present investigation, we
observed that the amount of phosphorylated AKT (Thr 308) is reduced with aging (Fig.
10). Whether these events are due to age-associated alterations in α-dystroglycan binding
to laminin-2 alone, or act in concert with other factors, is presently unclear. To further
investigate the role of AKT in cardiac apoptosis, we examined the levels and activation
of BAD. BAD is a pro-apoptotic, member of the Bcl-2 family that can displace Bax
binding from Bcl-2 and Bcl-XL, resulting in cell death [70]. However, phosphorylation
of BAD by AKT results in the binding of BAD to 14-3-3 proteins and the inhibition of
BAD binding to Bcl-2 and Bcl-XL thereby promoting cell survival [101]. With aging we
observed that the amount of BAD and phosphorylated BAD increased in the F344/N X
BN rat hearts (Fig. 11). The exact reasons why aging in the F344/N X BN rat heart may
be associated with increases in BAD and phosphorylated BAD protein levels are
unknown; however given our findings that aging increases apoptosis and caspase-3
activity, we suspect that these changes may represent a compensatory response to limit
further cell death in the aging heart.
Like AKT, X-chromosome-linked inhibitor of apoptosis protein (XIAP) is also
postulated to function in the prevention of apoptosis [102]. Here we report that aging
increases XIAP in the aging F344/N X BN rat heart (Fig. 12). It is thought that XIAP acts
to inhibit caspase-3 and -7 [103]. Similar to BAD, it is possible that aging in the F344/N
X BN rat heart increases XIAP protein levels as a means to limit further cell death.
Further experiments to test these possibilities will be useful to increase our understanding
of the connection between age-related changes in the DGC and cardiac myocyte
apoptosis.
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In summary, we show that the expression and localization of DGC proteins are
altered with aging in F344/N X BN rat . The extent to which combined changes in tissue
content and action of DGC participants plays a role in the heart cannot be assessed in the
absence of extensive studies to evaluate experimental manipulation of these proteins.
Nevertheless, in view of the known role DGC proteins play in the dystrophies, it may be
reasonable to speculate that these changes contribute to or are the result of age-associated
cardiac dysfunction.
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Appendix
Appendix A
Table 1. Body weight, heart weight and heart weight to body weight ratio of young adult
(6 month), aged (30 month) and very aged (36 month) F344/N X BN rat . An asterisk (*)
designates significant differences from 6-month age group (P < 0.05).

Table 1. Heart weight and body mass data

Age

Body mass, g
Heart mass, g
Heart wt. / Body.wt

6 months

30 months

36 months

406 ± 16.5

565 ± 40.04*

500.0 ± 17.5*

0.96 ± 0.08

1.81 ± 0.18*

1.66 ± 0.15*

0.237 ± 0.015

0.320 ± 0.025*

0.327 ± 0.021*

(mean ± SE), * Significantly different than 6 month group (P < 0.05).
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Figure legends

Figure 1. Aging alters the expression and localization of Dystrophin.
A. Protein isolates from the membrane content of hearts excised from adult (6 mo), aged
(30 mo) and very aged (36 mo) rats were analyzed by immunoblotting for age related
changes in Dystrophin protein expression. Data are presented as means ± SE. Insets:
representative blots for Dystrophin. (*) indicates significant difference from adult (6
month) value (P < 0.05). (†) indicates significant difference from 30 month value (P <
0.05). n = 5 for all groups. B,C: Immunolabeling of dystrophin in 6- (B) and 36-month
(C) hearts. Arrows indicate irregular and broken immunoreactive signaling along the
sarcolemma in the 36-month hearts. Bar = 25 µm.

Figure 2. Aging alters the expression and localization of dystroglycan A,D: Protein
isolates from the membrane content of hearts excised from adult (6 mo), aged (30 mo)
and very aged (36 mo) rats were analyzed by immunoblotting for age related changes in
α-and β-Dystroglycans protein expression. Data are presented as means ± SE. Insets:
representative blots for Dystrophin. (*) indicates significant difference from adult (6
month) value (P < 0.05). (†) indicates significant difference from 30 month muscles (P <
0.05). n = 5 for all groups. B,C: Immunolabeling of α-dystroglycan in 6- (B) and 36month (C) hearts. E,F: Immunolabeling of β-dystroglycan in 6- (E) and 36-month (F)
hearts. Bar = 25 µm.
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Figure 3. Aging alters the expression and localization of α-Sarcoglycan.
A. Protein isolates from the membrane content of hearts excised from adult (6 mo), aged
(30 mo) and very aged (36 mo) rats were analyzed by immunoblotting for age related
changes in α-Sarcoglycan protein expression. Data are presented as means ± SE. Insets:
representative blots for α-Sarcoglycan. (*) indicates significant difference from adult (6
month) value (P < 0.05). n = 5 for all groups. B,C: Immunolabeling of α-Sarcoglycan in
6- (B) and 36-month (C) hearts. Bar = 25 µm.

Figure 4. Aging alters the expression and localization of β-and δ-Sarcoglycans.
Protein isolates from the membrane content of hearts excised from adult (6 mo), aged (30
mo) and very aged (36 mo) rats were analyzed by immunoblotting for age related
changes in β-(A)and δ-Sarcoglycan(B) protein expression. Data are presented as means ±
SE. Insets: representative blots for α-Sarcoglycan. (*) indicates significant difference
from adult (6 month) value (P < 0.05). n = 5 for all groups.

Figure 5. Aging alters the membrane integrity. Loss of membrane integrity is
indicated by intracellular staining of rat IgG in 6- (A), 30-(B) and 36-month (C) hearts.
Note diffuse immunoreactive signaling within the cytoplasm of the 30-and 36 month
hearts. Bar = 25 µm.
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Figure 6. Aging increases the number of apoptotic nuclei.
A. Increase in the number of apoptotic nuclei with aging in 6-,30-and 36-month hearts.
(*) indicates significant difference from adult (6 month) value (P < 0.05). (†) indicates
significant difference from 30 month value (P < 0.05). Representative cross sections
showing the increases in nuclei exhibiting DNA strand breakage as determined by
TUNEL staining in 6-(B), 30-(C)and 36-month(D) hearts. Bar = 25 µm.

Figure 7. Aging alters the regulation of Caspase 3. Protein isolates from the cytosolic
content of hearts excised from adult (6 mo), aged (30 mo) and very aged (36 mo) rats
were analyzed by immunoblotting for age related changes in Caspase-3 protein
expression. A. cleaved 17 kDa fragment of Caspase 3. B. cleaved 19 kDa fragment of
Caspase 3. C. Full length Caspase 3. Data are presented as means ± SE.

Insets:

Corresponding representative blots for Caspase-3. (*) indicates significant difference
from adult (6 month) value (P < 0.05). (†) indicates significant difference from 30 month
value (P < 0.05). n = 5 for all groups.

Figure 8. Aging alters the regulation of Caspase 9. Protein isolates from the cytosolic
content of hearts excised from adult (6 mo), aged (30 mo) and very aged (36 mo) rats
were analyzed by immunoblotting for age related changes in Caspase-9 protein
expression. A. cleaved 38 kDa fragment of Caspase 3. B. cleaved 40 kDa fragment of
Caspase 3. C. Full length Caspase 3. Data are presented as means ± SE.

Insets:

Corresponding representative blots for Caspase-3. (*) indicates significant difference
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from adult (6 month) value (P < 0.05). (†) indicates significant difference from 30 month
value (P < 0.05). n = 5 for all groups.

Figure 9. Aging alters the regulation of α-fodrin content and cleavage.
A. Full length (240 kDa) α-fodrin content in 6-,30-and 36-month hearts.
B. Caspase dependent cleavage of α-fodrin (120 kDa). Data are presented as means ± SE.
Insets: representative blots for α-fodrin. (*) indicates significant difference from adult
(6 month) value (P < 0.05). (†) indicates significant difference from 30 month value (P <
0.05). n = 5 for all groups.

Figure 10. Aging alters the basal and phosphorylated levels of AKT. Membrane
protein isolates from hearts excised from 6-, 30-and 36-month hearts were analyzed by
immunoblotting for age-related changes in AKT (A) and p-AKT (Thr 308) (B) protein
expression. Data are presented as means ± SE.

Insets: Representative blots for

corresponding proteins. (*) indicates significant difference from adult (6 month) value (P
< 0.05). (†) indicates significant difference from 30 month value (P < 0.05). n = 5 for all
groups.

Figure 11. Aging alters the basal and phosphorylated levels of signaling molecule
BAD. Cytosolic protein isolates from hearts excised from 6-, 30-and 36-month hearts
were analyzed by immunoblotting for age-related changes in BAD (A), p-BAD (Ser
112)(B) and p-BAD (Ser136) (C) protein expression. Data are presented as means ± SE.
Insets: Representative blots for corresponding proteins. (*) indicates significant
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difference from adult (6 month) value (P < 0.05). (†) indicates significant difference from
30 month value (P < 0.05). n = 5 for all groups.

Figure 12. Aging alters the expression of XIAP. Cytosolic protein isolates from hearts
excised from 6-, 30-and 36-month hearts were analyzed by immunoblotting for agerelated changes in XIAP protein expression. Data are presented as means ± SE. Insets:
Representative blots for XIAP. (*) indicates significant difference from adult (6 month)
value (P < 0.05). n = 5 for all groups.
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Figure 1. Aging alters the regulation of dystrophin in the F344/N X BN rat heart
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Figure 2. Aging increases the amount of β-dystroglycan in the F344/N X BN rat
heart
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Figure 3. α-Sarcoglycan protein levels and localization is changed with aging
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Figure 4. β-and δ-Sarcoglycan protein levels are diminished in the aging heart
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Figure 5. Aging is associated with a loss of cardiac myocyte membrane integrity

Figure 6. Aging increases the number of apoptotic nuclei
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Figure 7. Aging increases the cleavage of caspase

3

-44-

Figure 8. Aging alters the regulation of caspase 9
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Figure 9. Aging alters the regulation of α-fodrin content and cleavage
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Figure 10. Aging in the F344/N X BN rat heart decreases the phosphorylation of
AKT
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Figure 11. Aging alters the amount and degree of BAD phosphorylation
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Figure 12. Aging alters the expression of XIAP
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Appendix B
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.

Dystrophin in cardiac muscle
Raw IOD values (relative percentage)

%C
%C
%C
%C
%C
%C

6 month
9.5
9.3
8.7
9.5
9.5
8.7

30 month
14.6
13.8
13.5
14.8
13.9
13.8

36 month
11.6
8.2
10.8
11.1
7.8
10.8

N
Mean
Strandard Deviation
Standard Error of the mean

6
9.2
0.394968
0.176635

6
14.06667
0.51251
0.229202

6
10.05
1.619568
0.724293

Relative Expression Level
Standard error of the mean

6 month
1
0.019199

30 month
1.528986
0.024913

36 month
1.092391
0.078727

% RE
SE

6 month
100
1.919948

30 month
152.8986
2.491321

36 month
109.2391
7.872747
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P > 0.050)

Equal Variance Test:

Passed (P = 0.104)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
30 Control vs. 36 Control
2.867
3
30 Control vs. 6 Control
1.167
2
6 Control vs. 36 Control
1.700
2

-53-

q
P
P < 0.050
6.605 <0.001
Yes
2.688
0.077
No
3.917
0.014
Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
α-dystroglycan in cardiac muscle
Raw IOD values (relative percentage)
6 month

30 month

36 month

%C

9.5

14.6

11.6

%C

9.3

13.8

8.2

%C

8.7

13.5

10.8

%C

9.5

14.8

11.1

%C

9.5

13.9

7.8

%C

8.7

13.8

10.8

N

6

6

6

Mean

9.2

14.06667

10.05

Strandard Deviation

0.394968

0.51251

1.619568

Standard Error of the mean

0.176635

0.229202

0.724293

6 month

30 month

36 month

Relative Expression Level

1

1.528986

1.092391

Standard error of the mean

0.019199

0.024913

0.078727

6 month

30 month

36 month

% RE

100

152.8986

109.2391

SE

1.919948

2.491321

7.872747
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.338)

Equal Variance Test:

Passed (P = 0.114)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.037).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 month vs. 30 month
1.350
3
36 month vs. 6 month
0.767
2
6 month vs. 30 month
0.583
2

q
4.055
2.303
1.752
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P P < 0.050
0.030
Yes
0.124
No
0.235
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
β-dystroglycan in cardiac muscle
Raw IOD values (relative percentage)
6 Control

30 Control

36 Control

%C

7.9

8.3

15.7

%C

11.3

8.3

14.8

%C

8.8

10.6

14.1

%C

8.1

8.3

15.7

%C

11.3

8.3

14.8

%C

8.8

10.6

13.9

N

6

6

6

Mean

9.366667

9.066667

14.83333

Strandard Deviation

1.540995

1.187715

0.763326

Standard Error of the mean

0.689154

0.531162

0.34137

6 month

30 month

36 month

Relative Expression Level

1

0.967972

1.58363

Standard error of the mean

0.073575

0.056708

0.036445

6 Control

30 Control

36 Control

% RE

100

96.79715

158.363

SE

7.357517

5.670771

3.644517
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P < 0.050)

The differences in the median values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.003)
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparison
Diff of Ranks
36 Control vs 30 Control
56.000
36 Control vs 6 Control
52.000
6 Control vs 30 Control
4.000

q
P < 0.05
4.282 Yes
5.888 Yes
0.453
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
α-Sarcoglycan in cardiac muscle
Raw IOD values (relative percentage)
6 months

30 months

36 months

%C

11.4

11.4

11

%C

12.9

11.2

9.3

%C

11.6

10.2

11

%C

11.4

11.7

10.9

%C

13.2

11.4

9.3

%C

11.5

10

10.5

N

6

6

6

Mean

12

10.98333

10.33333

Strandard Deviation

0.822192

0.705455

0.821381

Standard Error of the mean

0.367696

0.315489

0.367333

6 month

30 month

36 month

Relative Expression Level

1

0.915278

0.861111

Standard error of the mean

0.030641

0.026291

0.030611

6 months

30 months

36 months

% RE

100

91.52778

86.11111

SE

3.064129

2.629075

3.061106

%C
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P > 0.050)

Equal Variance Test:

Passed (P = 0.950)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.008).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
6 Control vs. 36 Control
1.667
3
6 Control vs. 30 Control
1.017
2
30 Control vs. 36 Control
0.650
2
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q
5.201
3.173
2.028

P P < 0.050
0.006
Yes
0.041
Yes
0.172
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
β-Sarcoglycan in cardiac muscle
Raw IOD values (relative percentage)
6 months

30 months

36 months

%C

12.1

10.6

11.4

%C

13

12

9.1

%C

11.8

9.5

10.5

%C

11.7

10.7

10.8

%C

13.4

12.1

9.3

%C

11.4

9.8

10.7

N

8

8

8

Mean

12.23333

10.78333

10.3

Strandard Deviation

0.791623

1.083359

0.905539

Standard Error of the mean

0.299205

0.409471

0.342261

6 month

30 month

36 month

Relative Expression Level

1

0.881471

0.841962

Standard error of the mean

0.024458

0.033472

0.027978

6 months

30 months

36 months

% RE

100

88.14714

84.19619

SE

2.44582

3.347176

2.797777
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.781)

Equal Variance Test:

Passed (P = 0.817)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.007).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
6 month vs. 36 month
1.933
3
6 month vs. 30 month
1.450
2
30 month vs. 36 month
0.483
2

q
5.067
3.800
1.267
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P P < 0.050
0.007
Yes
0.017
Yes
0.385
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
δ-Sarcoglycan in cardiac muscle
Raw IOD values (relative percentage)
6 months

30 months

36 months

%C

14.6

10.3

9.3

%C

12.6

9.7

11.2

%C

12.4

8.5

11.5

%C

14.3

10.4

9.4

%C

12.6

9.7

11.2

%C

12.4

8.5

11.6

N

8

8

8

Mean

13.15

9.516667

10.7

Strandard Deviation

1.015382

0.84004

1.058301

Standard Error of the mean

0.383778

0.317505

0.4

6 month

30 month

36 month

Relative Expression Level

1

0.723701

0.813688

Standard error of the mean

0.029185

0.024145

0.030418

6 months

30 months

36 months

% RE

100

72.37009

81.36882

SE

2.918465

2.414488

3.041825
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.267)

Equal Variance Test:

Passed (P = 0.968)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
6 month vs. 30 month
3.633
3
6 month vs. 36 month
2.450
2
36 month vs. 30 month
1.183
2

q
P
P < 0.050
9.120 <0.001
Yes
6.150 <0.001
Yes
2.970 0.053
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Caspase 3 (cleaved 17 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

6.6

7.9

13.2

%C

7.9

9.2

15.8

%C

7.9

7.9

23.7

%C

6.5

7.8

13

%C

6.5

9.1

14.3

%C

9.1

7.8

26

N

6

6

6

Mean

7.416667

8.283333

17.66667

Strandard Deviation

1.062858

0.673548

5.699006

Standard Error of the mean

0.475324

0.30122

2.548673

6 month

30 month

36 month

Relative Expression Level

1

1.116854

2.382022

Standard error of the mean

0.064089

0.040614

0.343641

6 months

30 months

36 months

% RE

100

111.6854

238.2022

SE

6.408869

4.06139

34.36413
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P = 0.016)

Equal Variance Test:

Passed (P = 0.052)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 months vs. 6 months
10.250
3
36 months vs. 30 months
9.383
2
30 months vs. 6 months
0.867
2

q
P
P < 0.050
7.451 <0.001
Yes
6.821 <0.001
Yes
0.630
0.662
No

-71-

Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Caspase 3 (cleaved 19 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

6.8

8.5

16.1

%C

6.8

8.5

17.8

%C

5.9

8.5

21.2

%C

6.2

8.9

17

%C

6.2

8

17.9

%C

6.2

8

21.4

N

6

6

6

Mean

6.35

8.4

18.56667

Strandard Deviation

0.367423

0.34641

2.2151

Standard Error of the mean

0.164317

0.154919

0.990623

6 month

30 month

36 month

Relative Expression Level

1

1.322835

2.923885

Standard error of the mean

0.025877

0.024397

0.156004

6 months

30 months

36 months

% RE

100

132.2835

292.3885

SE

2.587666

2.439675

15.60036
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P = 0.007)

Equal Variance Test:

Failed (P = 0.034)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 months vs. 6 months
12.217
3
36 months vs. 30 months
10.167
2
30 months vs. 6 months
2.050
2

q
P
P < 0.050
22.814 <0.001
Yes
18.985 <0.001
Yes
3.828
0.016
Yes

-73-

Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Caspase 3 (cleaved 35 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

12.1

13.1

9.2

%C

10.8

15.4

8.2

%C

7.5

13.7

10.1

%C

12.1

13.1

8.7

%C

10.7

14.8

8.4

%C

7.7

14.1

10.4

N

6

6

6

Mean

10.15

14.03333

9.166667

Strandard Deviation

2.06664

0.928799

0.909212

Standard Error of the mean

0.924229

0.415371

0.406612

6 month

30 month

36 month

Relative Expression Level

1

1.382594

0.90312

Standard error of the mean

0.091057

0.040923

0.04006

6 months

30 months

36 months

% RE

100

138.2594

90.31199

SE

9.105708

4.092328

4.00603
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P > 0.050)

Equal Variance Test:

Passed (P = 0.250)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
30 months vs. 36 months
4.867
3
30 months vs. 6 months
3.883
2
6 months vs. 36 months
0.983
2

q
P
P < 0.050
8.457 <0.001
Yes
6.748 <0.001
Yes
1.709 0.246
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Caspase 9 (cleaved 38 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 Control

30 Control

36 Control

%C

12.3

9.1

11.6

%C

10.9

9.3

11.6

%C

10.8

11.1

13.2

%C

12.2

9.5

11.7

%C

11.1

9.4

11.8

%C

10.9

10.8

12.7

N

6

6

6

Mean

11.36667

9.866667

12.1

Strandard Deviation

0.691857

0.85479

0.681175

Standard Error of the mean

0.309408

0.382274

0.304631

6 month

30 month

36 month

Relative Expression Level

1

0.868035

1.064516

Standard error of the mean

0.027221

0.033631

0.0268

6 Control

30 Control

36 Control

% RE

100

86.80352

106.4516

SE

2.722065

3.363113

2.680037
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P = <0.001)

Equal Variance Test:

Passed (P = 0.930)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 months vs. 30 months
2.233
3
36 months vs. 6 months
0.733
2
6 months vs. 30 months
1.500
2

q
P
P < 0.050
7.325 <0.001
Yes
2.405
0.110
No
4.920 0.004
Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Caspase 9 (cleaved 40 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

11.3

9

14.2

%C

9.2

10.2

13.6

%C

8.8

11.5

12.3

%C

9.8

10.7

13.9

%C

8.8

10.5

14.6

%C

9.8

12.8

9.2

N

6

6

6

Mean

9.616667

10.78333

12.96667

Strandard Deviation

0.938971

1.279714

2.004661

Standard Error of the mean

0.419921

0.572305

0.896512

6 month

30 month

36 month

Relative Expression Level

1

1.121317

1.348354

Standard error of the mean

0.043666

0.059512

0.093225

6 months

30 months

36 months

% RE

100

112.1317

134.8354

SE

4.366592

5.951181

9.322479
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P > 0.050)

Equal Variance Test:

Passed (P = 0.674)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.004).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 months vs. 6 months
3.350
3
36 months vs. 30 months
2.183
2
30 months vs. 6 months
1.167
2

q
5.559
3.623
1.936
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P P < 0.050
0.004
Yes
0.022
Yes
0.191
No

Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Caspase 9 (cleaved 51 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 Control

30 Control

36 Control

%C

9.4

9

12.3

%C

12.3

10.5

14.3

%C

7.8

11

13.4

%C

7.7

11

14.2

%C

11.6

10.8

14.8

%C

9.8

12.2

7.9

N

6

6

6

Mean

9.766667

10.75

12.81667

Strandard Deviation

1.900175

1.034891

2.562356

Standard Error of the mean

0.849784

0.462817

1.14592

6 month

30 month

36 month

Relative Expression Level

1

1.100683

1.312287

Standard error of the mean

0.087009

0.047387

0.11733

6 Control

30 Control

36 Control

% RE

100

110.0683

131.2287

SE

8.700863

4.738745

11.73297
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P > 0.050)

Equal Variance Test:

Passed (P = 0.476)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.044).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 months vs. 6 months
3.050
3
36 months vs. 30 months
2.067
2
30 months vs. 6 months
0.983
2

q
3.858
2.614
1.244
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P P < 0.050
0.039
Yes
0.084
No
0.393
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
Alpha-fodrin (cleaved 120 kDa) in cardiac muscle
Raw IOD values (relative percentage)

6 Control

30 Control

36 Control

%C

10.5

8.2

13

%C

11.8

7.8

13.8

%C

11.7

10.1

13.2

%C

10.5

8.4

13.5

%C

12.1

7.6

13.1

%C

11.8

10

13.1

N

6

6

6

Mean

11.4

8.683333

13.28333

Strandard Deviation

0.70993

1.096206

0.30605

Standard Error of the mean

0.31749

0.490238

0.13687

6 month

30 month

36 month

Relative Expression Level

1

0.761696

1.165205

Standard error of the mean

0.02785

0.043003

0.012006

6 Control

30 Control

36 Control

% RE

100

76.16959

116.5205

SE

2.785001

4.300334

1.200612
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P < 0.050)

The differences in the median values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.007)
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparison
Diff of Ranks
6 Control vs 30 Control
56.000
6 Control vs 36 Control
40.000
36 Control vs 30 Control
16.000

q
P < 0.05
4.282 Yes
4.529 Yes
1.812
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
alpha-fodrin (full length) in cardiac muscle
Raw IOD values (relative percentage)

6 Control

30 Control

36 Control

%C

12.5

10.6

12.1

%C

11.5

9.6

10.7

%C

11.6

10.5

11

%C

12.3

10.5

12.1

%C

11.4

9.7

10.8

%C

11.8

10.5

10.9

N

6

6

6

Mean

11.85

10.23333

11.26667

Strandard Deviation

0.450555

0.454606

0.653197

Standard Error of the mean

0.201494

0.203306

0.292119

6 month

30 month

36 month

Relative Expression Level

1

0.863572

0.950774

Standard error of the mean

0.017004

0.017157

0.024651

6 Control

30 Control

36 Control

% RE

100

86.35724

95.07736

SE

1.700375

1.715663

2.465137
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.115)

Equal Variance Test:

Passed (P = 0.791)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
6 Control vs. 30 Control
1.617
3
6 Control vs. 36 Control
0.583
2
36 Control vs. 30 Control
1.033
2
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q
P
P < 0.050
7.500 <0.001
Yes
2.706
0.075
No
4.794
0.004
Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
AKT in cardiac muscle
Raw IOD values (relative percentage)

6 month

30 month

36 month

%C

12.8

9

10.9

%C

12.8

9.9

10.9

%C

13

8.5

12.3

%C

12.7

9.2

11

%C

13.1

10.3

11

%C

13.2

9

10.6

N

6

6

6

Mean

12.93333

9.316667

11.11667

Strandard Deviation

0.196638

0.661564

0.598052

Standard Error of the mean

0.087939

0.29586

0.267457

6 month

30 month

36 month

Relative Expression Level

1

0.720361

0.859536

Standard error of the mean

0.006799

0.022876

0.02068

6 month

30 month

36 month

% RE

100

72.03608

85.95361

SE

0.679944

2.28758

2.067968
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P = 0.003)

Equal Variance Test:

Passed (P = 0.420)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
6 Control vs. 30 Control
3.617
3
6 Control vs. 36 Control
1.817
2
36 Control vs. 30 Control
1.800
2
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q
P
P < 0.050
16.802 <0.001
Yes
8.440 <0.001
Yes
8.362 <0.001
Yes

-90-

Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
p-AKT (Thr 308) in cardiac muscle
Raw IOD values (relative percentage)

6 Control

30 Control

36 Control

%C

13.8

10.1

10

%C

10.7

11

10.6

%C

15

9.2

9.5

%C

14.2

10.8

9.7

%C

11.5

10.8

10.6

%C

14.7

8.7

9

N

6

6

6

Mean

13.31667

10.1

9.9

Strandard Deviation

1.783723

0.954987

0.632456

Standard Error of the mean

0.797705

0.427083

0.282843

6 month

30 month

36 month

Relative Expression Level

1

0.758448

0.743429

Standard error of the mean

0.059903

0.032071

0.02124

6 Control

30 Control

36 Control

% RE

100

75.84481

74.34293

SE

5.990276

3.207132

2.123975
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.245)

Equal Variance Test:

Passed (P = 0.260)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
6 Control vs. 36 Control
3.417
3
6 Control vs. 30 Control
3.217
2
30 Control vs. 36 Control
0.200
2
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q
P
P < 0.050
6.838 <0.001
Yes
6.438 <0.001
Yes
0.400
0.781
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
BAD in cardiac muscle
Raw IOD values (relative percentage)
6 months

30 months

36 months

%C

9.6

9.8

10.4

%C

8

14.6

12.3

%C

8.7

12.6

13.9

%C

10.3

9.6

10.3

%C

7.5

14.4

12.7

%C

8.6

12.3

14.4

N

6

6

6

Mean

8.783333

12.21667

12.33333

Strandard Deviation

1.026483

2.158163

1.716586

Standard Error of the mean

0.459057

0.96516

0.76768

6 month

30 month

36 month

Relative Expression Level

1

1.390892

1.404175

Standard error of the mean

0.052265

0.109885

0.087402

6 months

30 months

36 months

% RE

100

139.0892

140.4175

SE

5.226455

10.98854

8.740195
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.597)

Equal Variance Test:

Passed (P = 0.280)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = 0.003).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means p
36 months vs. 6 months
3.550
3
36 months vs. 30 months
0.117
2
30 months vs. 6 months
3.433
2

q
5.119
0.168
4.950
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P P < 0.050
0.007
Yes
0.907
No
0.003
Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
p-BAD (Ser112) in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

7.2

15.1

12.2

%C

7.6

16

12.1

%C

8.2

15

6.6

%C

7

14.8

12.5

%C

7.5

16.2

11.9

%C

8

15.6

6.7

N

6

6

6

Mean

7.583333

15.45

10.33333

Strandard Deviation

0.457894

0.571839

2.859837

Standard Error of the mean

0.204776

0.255734

1.278958

6 month

30 month

36 month

Relative Expression Level

1

2.037363

1.362637

Standard error of the mean

0.027003

0.033723

0.168654

6 months

30 months

36 months

% RE

100

203.7363

136.2637

SE

2.700347

3.37232

16.86538
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Statistics
One Way Analysis of Variance
Normality Test:

Failed (P < 0.050)

The differences in the median values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.003)
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparison
Diff of Ranks
30 months vs 6 months
60.000
30 months vs 36 months
48.000
36 months vs 6 months
12.000

q
P < 0.05
4.588 Yes
5.435 Yes
1.359
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
p-BAD (Ser136) in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

7.9

10.3

14.4

%C

8.9

8.9

14.3

%C

9.9

8

17.5

%C

8.1

10.5

14.5

%C

8.5

9.2

14.2

%C

9.4

8.5

17.3

N

6

6

6

Mean

8.783333

9.233333

15.36667

Strandard Deviation

0.770498

0.991295

1.579451

Standard Error of the mean

0.344577

0.443321

0.706352

6 month

30 month

36 month

Relative Expression Level

1

1.051233

1.749526

Standard error of the mean

0.039231

0.050473

0.08042

6 months

30 months

36 months

% RE

100

105.1233

174.9526

SE

3.923078

5.047296

8.04196
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.209)

Equal Variance Test:

Passed (P = 0.701)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
36 control vs. 6 control
36 control vs. 30 control
30 control vs. 6 control

Diff of Means p
6.583
3
6.133
2
0.450
2
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q
P
P < 0.050
13.843 <0.001
Yes
12.897 <0.001
Yes
0.946 0.514
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films.
XIAP in cardiac muscle
Raw IOD values (relative percentage)

6 months

30 months

36 months

%C

5.1

11.3

14.6

%C

6.4

12.1

14.2

%C

6.4

15.6

14.2

%C

4.7

11.1

15.2

%C

6.2

12.1

14.6

%C

6.2

15.8

14.2

N

6

6

6

Mean

5.833333

13

14.5

Strandard Deviation

0.739369

2.131666

0.394968

Standard Error of the mean

0.330656

0.95331

0.176635

6 month

30 month

36 month

Relative Expression Level

1

2.228571

2.485714

Standard error of the mean

0.056684

0.163425

0.03028

6 months

30 months

36 months

% RE

100

222.8571

248.5714

SE

5.668387

16.34246

3.028032
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Statistics
One Way Analysis of Variance
Normality Test:

Passed (P = 0.096)

Equal Variance Test:

Passed (P = 0.138)

The differences in the mean values among the treatment groups are greater than would be
expected by chance; there is a statistically significant difference (P = <0.001).
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
36 control vs. 6 control
36 control vs. 30 control
30 control vs. 6 control

Diff of Means p
8.667
3
1.500
2
7.167
2
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q
P
P < 0.050
16.053 <0.001
Yes
2.778 0.068
No
13.274 <0.001
Yes

Chapter 4
Conclusions
The research findings described herein can be summarized in five major findings:
1. Aging was found to alter the regulation of dystrophin glycoprotein complex in cardiac
muscle. The content of dystroglycans is significantly increased with aging in F344/N X
BN rat hearts. Conversely, aging significantly decreased the content of sarcoglycans in
F344/N X BN rat hearts.
2. Aging is associated with alterations in localization of dystrophin glycoprotein complex
proteins along the sarcolemma of F344/N X BN rat cardiomyocytes.
3. Age-associated alterations in membrane dystrophin content are associated with changes
in sarcolemmal stability of F344/N X BN rat cardiomyocytes.
4. Aging in the F344/N X BN rat heart is associated with increased TUNEL positive
staining and activation of mitochondrial dependent caspases pathway of apoptosis.
5. The regulation of anti- and pro-apoptotic regulators with Aging in the F344/N X BN rat
heart is associated with alterations in AKT phosphorylation and AKT-associated
signaling.

Further directions
Future directions for research based on this study should focus on the
mechanisms underlying the altered regulation and localization of dystrophin glycoprotein
complex in cardiomyocytes with aging.
Recent data has suggested that disruption of the DGC may be involved in
mediating the progression of cardiac hypertrophy and failure. A better understanding of
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the signaling mechanisms of DGC in mediating cardiomyocyte cell death may provide
insight in to the cardiac muscle aging. Currently aging and apoptosis of cardiac muscle
are under investigation.
Additionally, investigation of the mechanical link between DGC and
extracellular matrix through β-dystroglycan may provide better understanding of the
cardiac muscle aging. Further elucidating the specific signaling proteins that mediate
altered regulation of DGC and increased apoptosis with aging in cardiac muscle can help
better pharmacological treatment of age associated cardiac dysfunction.

-106-

References:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

Lakatta, E.G., Age-associated cardiovascular changes in health: impact on
cardiovascular disease in older persons. Heart Fail Rev, 2002. 7(1): p. 29-49.
Juhaszova, M., et al., Protection in the aged heart: preventing the heart-break of
old age? Cardiovasc Res, 2005. 66(2): p. 233-44.
Saner, H., [Cardiovascular system and aging]. Ther Umsch, 2005. 62(12): p. 82735.
Walker, E.M., Jr., et al., Age-associated changes in hearts of male Fischer
344/Brown Norway F1 rats. Ann Clin Lab Sci, 2006. 36(4): p. 427-38.
Ervasti, J.M. and K.P. Campbell, A role for the dystrophin-glycoprotein complex
as a transmembrane linker between laminin and actin. J Cell Biol, 1993. 122(4):
p. 809-23.
Campbell, K.P. and S.D. Kahl, Association of dystrophin and an integral
membrane glycoprotein. Nature, 1989. 338(6212): p. 259-62.
Hack, A.A., et al., Muscle degeneration without mechanical injury in sarcoglycan
deficiency. Proc Natl Acad Sci U S A, 1999. 96(19): p. 10723-8.
Kawada, T., et al., A novel scheme of dystrophin disruption for the progression of
advanced heart failure. Biochim Biophys Acta, 2005. 1751(1): p. 73-81.
Danialou, G., et al., Dystrophin-deficient cardiomyocytes are abnormally
vulnerable to mechanical stress-induced contractile failure and injury. Faseb J,
2001. 15(9): p. 1655-7.
Lakatta, E.G. and S.J. Sollott, Perspectives on mammalian cardiovascular aging:
humans to molecules. Comp Biochem Physiol A Mol Integr Physiol, 2002.
132(4): p. 699-721.
Lakatta, E.G. and H.A. Spurgeon, Effect of exercise on cardiac muscle
performance in aged rats. Fed Proc, 1987. 46(5): p. 1844-9.
Li, Y., et al., Age-related differences in effect of exercise training on cardiac
muscle function in rats. Am J Physiol, 1986. 251(1 Pt 2): p. H12-8.
Spurgeon, H.A., M.F. Steinbach, and E.G. Lakatta, Chronic exercise prevents
characteristic age-related changes in rat cardiac contraction. Am J Physiol,
1983. 244(4): p. H513-8.
Templeton, G.H., et al., Influence of aging on left ventricular hemodynamics and
stiffness in beagles. Circ Res, 1979. 44(2): p. 189-94.
Zhou, Y.Y., E.G. Lakatta, and R.P. Xiao, Age-associated alterations in calcium
current and its modulation in cardiac myocytes. Drugs Aging, 1998. 13(2): p.
159-71.
Cafagna, D. and E. Ponte, [Morphological and functional aspects of the
cardiovascular system related to aging: does "aging heart" exist?]. Minerva Med,
1997. 88(12): p. 491-500.
Rice, K.M., et al., Effects of aging on pressure-induced MAPK activation in the
rat aorta. Pflugers Arch, 2005. 450(3): p. 192-9.
Olivetti, G., et al., Cardiomyopathy of the aging human heart. Myocyte loss and
reactive cellular hypertrophy. Circ Res, 1991. 68(6): p. 1560-8.
Melissari, M., et al., [The aging of the heart: weight and structural changes in the
left ventricle with age]. G Ital Cardiol, 1991. 21(2): p. 119-30.

-107-

20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.

32.
33.
34.
35.
36.

Haider, A.W., et al., Increased left ventricular mass and hypertrophy are
associated with increased risk for sudden death. J Am Coll Cardiol, 1998. 32(5):
p. 1454-9.
Gerstenblith, G., et al., Echocardiographic assessment of a normal adult aging
population. Circulation, 1977. 56(2): p. 273-8.
Downes, T.R., et al., Mechanism of altered pattern of left ventricular filling with
aging in subjects without cardiac disease. Am J Cardiol, 1989. 64(8): p. 523-7.
Morales, M.A., et al., Age dependency of myocardial structure: a quantitative
two-dimensional echocardiographic study in a normal population.
Echocardiography, 2000. 17(3): p. 201-8.
Lipman, R.D., Pathobiology of aging rodents: inbred and hybrid models. Exp
Gerontol, 1997. 32(1-2): p. 215-28.
Weindruch, R., Animal models for use in aging research. J. Gerontol, 1995. 50A:
p. 121-127.
Lakatta, E.G., Introduction: chronic heart failure in older persons. Heart Fail
Rev, 2002. 7(1): p. 5-8.
Hacker, T.A., et al., Age-related changes in cardiac structure and function in
Fischer 344 x Brown Norway hybrid rats. Am J Physiol Heart Circ Physiol, 2006.
290(1): p. H304-11.
Koenig, M., A.P. Monaco, and L.M. Kunkel, The complete sequence of
dystrophin predicts a rod-shaped cytoskeletal protein. Cell, 1988. 53(2): p. 21928.
Lapidos, K.A., R. Kakkar, and E.M. McNally, The dystrophin glycoprotein
complex: signaling strength and integrity for the sarcolemma. Circ Res, 2004.
94(8): p. 1023-31.
Madhavan, R. and H.W. Jarrett, Phosphorylation of dystrophin and alphasyntrophin by Ca(2+)-calmodulin dependent protein kinase II. Biochim Biophys
Acta, 1999. 1434(2): p. 260-74.
Walsh, M.P., et al., Characterization of the recombinant C-terminal domain of
dystrophin: phosphorylation by calmodulin-dependent protein kinase II and
dephosphorylation by type 2B protein phosphatase. Biochemistry, 1995. 34(16):
p. 5561-8.
Shemanko, C.S., et al., Phosphorylation of the carboxyl terminal region of
dystrophin by mitogen-activated protein (MAP) kinase. Mol Cell Biochem, 1995.
152(1): p. 63-70.
Luise, M., et al., Dystrophin is phosphorylated by endogenous protein kinases.
Biochem J, 1993. 293 (Pt 1): p. 243-7.
Madhavan, R. and H.W. Jarrett, Calmodulin-activated phosphorylation of
dystrophin. Biochemistry, 1994. 33(19): p. 5797-804.
Judge, L.M., M. Haraguchiln, and J.S. Chamberlain, Dissecting the signaling and
mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci, 2006.
119(Pt 8): p. 1537-46.
Kamogawa, Y., et al., Dystrophin-deficient myocardium is vulnerable to pressure
overload in vivo. Cardiovasc Res, 2001. 50(3): p. 509-15.

-108-

37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.

Hutter, O.F., F.L. Burton, and D.L. Bovell, Mechanical properties of normal and
mdx mouse sarcolemma: bearing on function of dystrophin. J Muscle Res Cell
Motil, 1991. 12(6): p. 585-9.
Cavaldesi, M., et al., Association of the dystroglycan complex isolated from
bovine brain synaptosomes with proteins involved in signal transduction. J
Neurochem, 1999. 72(4): p. 1648-55.
Ilsley, J.L., M. Sudol, and S.J. Winder, The interaction of dystrophin with betadystroglycan is regulated by tyrosine phosphorylation. Cell Signal, 2001. 13(9):
p. 625-32.
Imamura, M., et al., A sarcoglycan-dystroglycan complex anchors Dp116 and
utrophin in the peripheral nervous system. Hum Mol Genet, 2000. 9(20): p. 3091100.
Rentschler, S., et al., The WW domain of dystrophin requires EF-hands region to
interact with beta-dystroglycan. Biol Chem, 1999. 380(4): p. 431-42.
Saito, F., et al., Characterization of the transmembrane molecular architecture of
the dystroglycan complex in schwann cells. J Biol Chem, 1999. 274(12): p. 82406.
Yang, B., et al., SH3 domain-mediated interaction of dystroglycan and Grb2. J
Biol Chem, 1995. 270(20): p. 11711-4.
Yoshida, T., et al., Bidirectional signaling between sarcoglycans and the integrin
adhesion system in cultured L6 myocytes. J Biol Chem, 1998. 273(3): p. 1583-90.
Sonoda, Y., et al., FAK is the upstream signal protein of the phosphatidylinositol
3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a
human glioblastoma cell line. J Biol Chem, 1999. 274(15): p. 10566-70.
Burgering, B.M. and P.J. Coffer, Protein kinase B (c-Akt) in phosphatidylinositol3-OH kinase signal transduction. Nature, 1995. 376(6541): p. 599-602.
Chen, H.C. and J.L. Guan, Association of focal adhesion kinase with its potential
substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A, 1994. 91(21):
p. 10148-52.
Datta, S.R., A. Brunet, and M.E. Greenberg, Cellular survival: a play in three
Akts. Genes Dev, 1999. 13(22): p. 2905-27.
Beitner-Johnson, D., et al., Hypoxia activates Akt and induces phosphorylation of
GSK-3 in PC12 cells. Cell Signal, 2001. 13(1): p. 23-7.
Langenbach, K.J. and T.A. Rando, Inhibition of dystroglycan binding to laminin
disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle
Nerve, 2002. 26(5): p. 644-53.
Ozawa, E., et al., From dystrophinopathy to sarcoglycanopathy: evolution of a
concept of muscular dystrophy. Muscle Nerve, 1998. 21(4): p. 421-38.
Noguchi, S., et al., Formation of sarcoglycan complex with differentiation in
cultured myocytes. Eur J Biochem, 2000. 267(3): p. 640-8.
Yoshida, M., et al., Biochemical evidence for association of dystrobrevin with the
sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy.
Hum Mol Genet, 2000. 9(7): p. 1033-40.
Yoshida, T., et al., Expression of a dystrophin-sarcoglycan complex in serumdeprived BC3H1 cells and involvement of alpha-sarcoglycan in substrate
attachment. Biochem Biophys Res Commun, 1996. 225(1): p. 11-5.

-109-

55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.

Lakatta, E.G., Aging and cardiovascular structure and function in healthy
sedentary humans. Aging (Milano), 1998. 10(2): p. 162-4.
Kuller, L.H. and K. Sutton-Tyrrell, Aging and cardiovascular disease. Use of
subclinical measurements. Cardiol Clin, 1999. 17(1): p. 51-65, viii.
Lakatta, E.G., Cardiovascular aging in health. Clin Geriatr Med, 2000. 16(3): p.
419-44.
Lipman, R.D., et al., Pathologic characterization of brown Norway, brown
Norway x Fischer 344, and Fischer 344 x brown Norway rats with relation to
age. J Gerontol A Biol Sci Med Sci, 1996. 51(1): p. B54-9.
Wheeler, M.T., et al., The sarcoglycan complex in striated and vascular smooth
muscle. Cold Spring Harb Symp Quant Biol, 2002. 67: p. 389-97.
Hein, S., et al., The role of the cytoskeleton in heart failure. Cardiovasc Res,
2000. 45(2): p. 273-8.
Kostin, S., et al., The cytoskeleton and related proteins in the human failing heart.
Heart Fail Rev, 2000. 5(3): p. 271-80.
Beggs, A.H., Dystrophinopathy, the expanding phenotype. Dystrophin
abnormalities in X-linked dilated cardiomyopathy. Circulation, 1997. 95(10): p.
2344-7.
Frank, J.S., et al., Subcellular distribution of dystrophin in isolated adult and
neonatal cardiac myocytes. Am J Physiol, 1994. 267(6 Pt 1): p. C1707-16.
Ortiz-Lopez, R., et al., Evidence for a dystrophin missense mutation as a cause of
X-linked dilated cardiomyopathy. Circulation, 1997. 95(10): p. 2434-40.
Petrof, B.J., et al., Dystrophin protects the sarcolemma from stresses developed
during muscle contraction. Proc Natl Acad Sci U S A, 1993. 90(8): p. 3710-4.
Towbin, H., T. Staehelin, and J. Gordon, Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
1979. Biotechnology, 1992. 24: p. 145-9.
Chockalingam, P.S., et al., Dystrophin-glycoprotein complex and Ras and Rho
GTPase signaling are altered in muscle atrophy. Am J Physiol Cell Physiol,
2002. 283(2): p. C500-11.
Green, A.M. and N.D. Steinmetz, Monitoring apoptosis in real time. Cancer J,
2002. 8(2): p. 82-92.
Zhang, J.H., Y. Zhang, and B. Herman, Caspases, apoptosis and aging. Ageing
Res Rev, 2003. 2(4): p. 357-66.
Hengartner, M.O., The biochemistry of apoptosis. Nature, 2000. 407(6805): p.
770-6.
Saraste, A. and K. Pulkki, Morphologic and biochemical hallmarks of apoptosis.
Cardiovasc Res, 2000. 45(3): p. 528-37.
Martin, S.J., et al., Proteolysis of fodrin (non-erythroid spectrin) during
apoptosis. J Biol Chem, 1995. 270(12): p. 6425-8.
Janicke, R.U., et al., Caspase-3 is required for alpha-fodrin cleavage but
dispensable for cleavage of other death substrates in apoptosis. J Biol Chem,
1998. 273(25): p. 15540-5.
Vanags, D.M., et al., Protease involvement in fodrin cleavage and
phosphatidylserine exposure in apoptosis. J Biol Chem, 1996. 271(49): p. 3107585.

-110-

75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.

86.
87.
88.
89.
90.
91.
92.

Song, G., G. Ouyang, and S. Bao, The activation of Akt/PKB signaling pathway
and cell survival. J Cell Mol Med, 2005. 9(1): p. 59-71.
Downward, J., PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol, 2004.
15(2): p. 177-82.
Hu, P., et al., Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in
counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem,
2004. 279(47): p. 49420-9.
Kim, J.E. and S.R. Tannenbaum, Insulin regulates cleavage of procaspase-9 via
binding of X chromosome-linked inhibitor of apoptosis protein in HT-29 cells.
Cancer Res, 2004. 64(24): p. 9070-5.
Sprott, R., Development of animal models of aging at the National Institute on
Aging. Neurobiol Aging, 1991. 12: p. 635-638.
Brown, R.H., Jr., Dystrophin-associated proteins and the muscular dystrophies.
Annu Rev Med, 1997. 48: p. 457-66.
Kirschner, J. and C.G. Bonnemann, The congenital and limb-girdle muscular
dystrophies: sharpening the focus, blurring the boundaries. Arch Neurol, 2004.
61(2): p. 189-99.
Malhotra, S.B., et al., Frame-shift deletions in patients with Duchenne and Becker
muscular dystrophy. Science, 1988. 242(4879): p. 755-9.
Muntoni, F., et al., Brief report: deletion of the dystrophin muscle-promoter
region associated with X-linked dilated cardiomyopathy. N Engl J Med, 1993.
329(13): p. 921-5.
Towbin, J.A., K.R. Bowles, and N.E. Bowles, Etiologies of cardiomyopathy and
heart failure. Nat Med, 1999. 5(3): p. 266-7.
Cote, P.D., H. Moukhles, and S. Carbonetto, Dystroglycan is not required for
localization of dystrophin, syntrophin, and neuronal nitric-oxide synthase at the
sarcolemma but regulates integrin alpha 7B expression and caveolin-3
distribution. J Biol Chem, 2002. 277(7): p. 4672-9.
Sampaolesi, M., et al., Stretch-induced cell damage in sarcoglycan-deficient
myotubes. Pflugers Arch, 2001. 442(2): p. 161-70.
Rando, T.A., Role of nitric oxide in the pathogenesis of muscular dystrophies: a
"two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech, 2001.
55(4): p. 223-35.
Centurione, L., et al., Age-related death-survival balance in myocardium: an
immunohistochemical and biochemical study. Mech Ageing Dev, 2002. 123(4): p.
341-50.
Centurione, L., et al., Correlations between protein kinase C zeta signaling and
morphological modifications during rat heart development and aging. Mech
Ageing Dev, 2003. 124(8-9): p. 957-66.
Nitahara, J.A., et al., Intracellular calcium, DNase activity and myocyte apoptosis
in aging Fischer 344 rats. J Mol Cell Cardiol, 1998. 30(3): p. 519-35.
Kajstura, J., et al., Necrotic and apoptotic myocyte cell death in the aging heart of
Fischer 344 rats. Am J Physiol, 1996. 271(3 Pt 2): p. H1215-28.
Kwak, H.B., W. Song, and J.M. Lawler, Exercise training attenuates age-induced
elevation in Bax/Bcl-2 ratio, apoptosis, and remodeling in the rat heart. Faseb J,
2006. 20(6): p. 791-3.

-111-

93.
94.
95.
96.
97.
98.
99.
100.

101.
102.
103.

Phaneuf, S. and C. Leeuwenburgh, Cytochrome c release from mitochondria in
the aging heart: a possible mechanism for apoptosis with age. Am J Physiol
Regul Integr Comp Physiol, 2002. 282(2): p. R423-30.
Goldspink, D.F., J.G. Burniston, and L.B. Tan, Cardiomyocyte death and the
ageing and failing heart. Exp Physiol, 2003. 88(3): p. 447-58.
Cai, J., J. Yang, and D.P. Jones, Mitochondrial control of apoptosis: the role of
cytochrome c. Biochim Biophys Acta, 1998. 1366(1-2): p. 139-49.
Porter, A.G. and R.U. Janicke, Emerging roles of caspase-3 in apoptosis. Cell
Death Differ, 1999. 6(2): p. 99-104.
Cohen, G.M., Caspases: the executioners of apoptosis. Biochem J, 1997. 326 (Pt
1): p. 1-16.
Ermak, G. and K.J. Davies, Calcium and oxidative stress: from cell signaling to
cell death. Mol Immunol, 2002. 38(10): p. 713-21.
Lynch, J.M., et al., Assembling pieces of the cardiac puzzle; calreticulin and
calcium-dependent pathways in cardiac development, health, and disease. Trends
Cardiovasc Med, 2006. 16(3): p. 65-9.
Okada, K., et al., Prolonged endoplasmic reticulum stress in hypertrophic and
failing heart after aortic constriction: possible contribution of endoplasmic
reticulum stress to cardiac myocyte apoptosis. Circulation, 2004. 110(6): p. 70512.
Masters, S.C., et al., Survival-promoting functions of 14-3-3 proteins. Biochem
Soc Trans, 2002. 30(4): p. 360-5.
Holcik, M., H. Gibson, and R.G. Korneluk, XIAP: apoptotic brake and promising
therapeutic target. Apoptosis, 2001. 6(4): p. 253-61.
Salvesen, G.S. and C.S. Duckett, IAP proteins: blocking the road to death's door.
Nat Rev Mol Cell Biol, 2002. 3(6): p. 401-10.

-112-

Curriculum Vitae
Sunil K Kakarla
Work:
R C Byrd Biotechnology centre, 217
College of Science
1 John Marshall Drive
Huntington, WV 25755

kakarla@marshall.edu
Work: (304)696-3267
Home: (304)521-1974
Cell : (814)504-3341

Home: 3363, RT 60 E, #B 4, Huntington, WV 25705
EDUCATION:
M.S. in Biology: College of Science, Marshall University, Huntington, WV
Concentrations: Molecular Physiology
Thesis title: Age-related DGC structure and function in the F344/N X BN rat heart.
Advisor: Dr. Eric R. Blough
B.V.Sc & A.H (Bachelor of Veterinary Science and Animal Husbandry, Equivalent of
D.V.M): College of Veterinary Science, Acharya N. G. Ranga Agricultural
University, Tirupati, A.P, India.
PROFESSIONAL EXPERIENCE:
Poultry Pathologist: Nov- 1999 to June- 2005. Vijayanagaram Hatcheries Pvt Ltd,
Visakhapatnam, A.P, India.
Veterinary doctor: From July 2000 to Aug 2005. Animal Husbandry
Department, Government of A. P, India.
Research Assistant: Fall 2005 to till now. Dr. Eric Blough, Professor, COS,
Marshall University.
PUBLICATIONS:
- Effects of Diabetes on pressure induced MAPKs signaling in the inferior vena cava
of diabetic and non-diabetic Zucker Rats; K. M. Rice1,D.H.Desai2, Sunil K.Kakarla1 ,
and E. R. Blough1,2 ; 1 Department of Biological Sciences, Marshall University, 2
Department of Physiology, Marshall University, Joan C. Edwards School of Medicine;
Cardiovascular Diabetology August 2006.

-113-

- Aging influences multiple indices of oxidative stress in the heart of the Fischer
344/NNia x Brown Norway/BiNia rat. Shinichi Asano1, Kevin M. Rice1, Sunil K.
Karkarla1, and Eric R Blough1,2: 1Department of Biological Sciences, Marshall
University, 2 Department of Physiology, Marshall University, Joan C. Edwards School of
Medicine.(accepted)
SUBMITTED:
- High force contraction-induced mitogen activated protein kinase (MAPK) signaling
in the rat skeletal muscle is altered in diabetes. Anjaiah Katta1, Kevin M. Rice1,
Deborah L. Preston1, Sunil K. Kakarla1, and 1,2Eric R Blough: 1 Department of
Biological Sciences, Marshall University, 2 Department of Physiology, Marshall
University, Joan C. Edwards School of Medicine (In review).
IN PREPARATION:
- Altered dystrophin-glycoprotein complex composition in the aging rat heart. Sunil
K. Karkarla1, Kevin M. Rice1, Devashich H. Desai2, and Eric R Blough1,2: Department
of Biological Sciences, Marshall University, 2 Department of Physiology, Marshall
University, Joan C. Edwards School of Medicine (In preparation)
- Aging alters the NFκ-B signaling in F1 skeletal muscle; K. M. Rice1, Sunil
K.Kakarla1 and E. R. Blough1,2 ; 1 Department of Biological Sciences, Marshall
University, 2 Department of Physiology, Marshall University, Joan C. Edwards School of
Medicine (In preparation)
- Sheer stress induces MAPK and p70s6k signaling in A7r5 smooth muscle cells; K.
M. Rice1 , Sunil K.Kakarla1and E. R. Blough1,2 ; 1 Department of Biological Sciences,
Marshall University, 2 Department of Physiology, Marshall University, Joan C. Edwards
School of Medicine (In preparation)
- Diabetes alters the DGC complex and ROS in Cardiac Muscle; K. M. Rice1 , Sunil
K.Kakarla1 a,nd E. R. Blough1,2 ; 1 Department of Biological Sciences, Marshall
University, 2 Department of Physiology, Marshall University, Joan C. Edwards School of
Medicine (In preparation)
PAPERS PRESENTED AT CONFERENCES:
Altered dystrophin-glycoprotein complex composition in the aging rat heart. Sunil K.
Karkarla, Kevin M. Rice, Devashich H. Desai, Paulette S. Wehner, and Eric R Blough:
Presented at the ACSM Conference on Integrative Physiology of Exercise: Discovery and
Application of Cardiovascular-Pulmonary and Metabolic Science, Indianapolis, IN, 2006

-114-

Shear stress activates AKT in cultured A7r5 aortic smooth muscle cell line. Sriram P.
Mupparaju, Devashish H. Desai, Kevin M. Rice, Sunil K. Karkarla, and Eric R Blough:
Presented at the ACSM Conference on Integrative Physiology of Exercise: Discovery and
Application of Cardiovascular-Pulmonary and Metabolic Science, Indianapolis, IN, 2006
Pressure –induced regulation of mitogen activated protein kinases in the rat inferior
vena cave. Devashish H. Desai, Kevin M. Rice, Sunil K. Karkarla, Anjaiah Katta,
Deborah L. Preston, Ernest M. Walker Jr., Paulette S. Wehner, and Eric R Blough:
Presented at the ACSM Conference on Integrative Physiology of Exercise: Discovery and
Application of Cardiovascular-Pulmonary and Metabolic Science, Indianapolis, IN, 2006
High force contraction-induced mitogen activated protein kinase (MAPK) signaling in
the rat skeletal muscle is altered in diabetes. Anjaiah Katta, Kevin M. Rice, Deborah L.
Preston, Sunil K. Kakarla, Elli Yokochi, J. Brandon Armstrong, and Eric R Blough:
Presented at the ACSM Conference on Integrative Physiology of Exercise: Discovery and
Application of Cardiovascular-Pulmonary and Metabolic Science, Indianapolis, IN, 2006
HSPs are altered with age associated increase in oxidative strew in the heart of the
Fischer 344/Nnia X Brown Norway/Binia rat. Shinichi Asano, Kevin M. Rice, Sunil K.
Karkarla, Paulette S. Wehner, Ernest M. Walker Jr., and Eric R Blough: Presented at the
ACSM Conference on Integrative Physiology of Exercise: Discovery and Application of
Cardiovascular-Pulmonary and Metabolic Science, Indianapolis, IN, 2006
PROFESSIONAL MEMBERSHIPS:
Member of Indian Veterinary Council
Eligibility to practice veterinary medicine in India.
Member of Andhra Pradesh Veterinary Association
License to practice veterinary medicine in the state of Andhra Pradesh, India.
American College of Sport Medicine (ACSM)
RESEARCH SKILLS:
• Protein Identification by MALDI- TOF Mass Spectrometry.
• Identification of Post-translational modification of proteins.
• Protein and peptide characterization by LCQ.
• Immunohistochemistry.
• Flourescent and Confocal Microscopy.
• Different staining procedures.
• Sample preparation from Laboratory animals.
• Protein Quantitation using Bradford assay.
• SDS gel electrophoresis.
• Immunoblotting, Immunoprecipitation and Westerns.

-115-

•
•
•
•
•
•
•

Comparative image quantitation using Densitometry.
High Performance Liquid Chromatography.
DNA and Protein gel electrophoresis.
Flow cytometry.
Cell and tissue culture.
small animal surgery.
Handling of Laboratory animals.

REFERENCES:

Dr. Eric R. Blough, Assosciate Professor
Department of Biology
Director, Laboratory of Molecular physiology
Marshall University, Huntington, WV
(304)696-2708
Dr. Charles Somerville, Professor
Department of Biology
Marshall University, Huntington, WV
(304)696-2424
Dr. David Mallory, Professor
Department of Biology
Marshall University, Huntington, WV
(304)696-2353
Marcia Harrison, Professor
Department of Biology,
Marshall University, Huntington, WV
(304) 696-4867

-116-

